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Discovery of Cephalosporin-3'-Diazeniumdiolates That Show Dual Antibacterial 
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Abstract 
The formation of biofilms provides a formidable defense for many bacteria against antibiotics and host 
immune responses. As a consequence, biofilms are thought to be the root cause of most chronic 
infections, including those occurring on medical indwelling devices, endocarditis, urinary tract infections, 
diabetic and burn wounds, and bone and joint infections. In cystic fibrosis (CF), chronic Pseudomonas 
aeruginosa (P. aeruginosa) respiratory infections are the leading cause of morbidity and mortality in 
adults. Previous studies have shown that many bacteria can undergo a coordinated dispersal event in the 
presence of low concentrations of nitric oxide (NO), suggesting that NO could be used to initiate biofilm 
dispersal in chronic infections, enabling clearance of the more vulnerable planktonic cells. In this study, 
we describe efforts to create "all-in-one" cephalosporin-based NO donor prodrugs (cephalosporin-3'-
diazeniumdiolates, C3Ds) that show both direct β-lactam mediated antibacterial activity and antibiofilm 
effects. Twelve novel C3Ds were synthesized and screened against a panel of P. aeruginosa CF clinical 
isolates and other human pathogens. The most active compound, AMINOPIP2 
((Z)-1-(4-(2-aminoethyl)piperidin-1-yl)-2-(((6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-carbo
1-oxide)-ceftazidime 12, showed higher antibacterial potency than its parent cephalosporin and front-line 
antipseudomonal antibiotic ceftazidime, good stability against β-lactamases, activity against ceftazidime-
resistant P. aeruginosa in vitro biofilms, and efficacy equivalent to ceftazidime in a murine P. aeruginosa 
respiratory infection model. The results support further evaluation of AMINOPIP2-ceftazidime 12 for P. 
aeruginosa lung infections in CF and a broader study of "all-in-one" C3Ds for other chronic infections. 
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 The formation of biofilms provides a formidable defense for many bacteria against 
antibiotics and host immune responses. As a consequence, biofilms are thought to be the root 
cause of most chronic infections, including those occurring on medical indwelling devices, 
endocarditis, urinary tract infections, diabetic and burn wounds and bone and joint infections. 
In cystic fibrosis (CF), chronic Pseudomonas aeruginosa respiratory infections are the leading 
cause of morbidity and mortality in adults. Previous studies have shown that many bacteria can 
undergo a coordinated dispersal event in the presence of low concentrations of nitric oxide 
(NO), suggesting that NO could be used to initiate biofilm dispersal in chronic infections, 
enabling clearance of the more vulnerable planktonic cells. In this study, we describe efforts to 
create ‘all-in-one’ cephalosporin-based NO donor prodrugs (cephalosporin-3´-
diazeniumdiolates, C3Ds) that show both direct -lactam mediated antibacterial activity and 
antibiofilm effects. Twelve novel C3Ds were synthesized and screened against a panel of P. 
aeruginosa CF clinical isolates and other human pathogens. The most active compound, 
AMINOPIP2-ceftazidime 12, showed higher antibacterial potency than its parent 
cephalosporin and front-line antipseudomonal antibiotic ceftazidime, good stability against -
lactamases, activity against ceftazidime-resistant P. aeruginosa in vitro biofilms and efficacy 
equivalent to ceftazidime in a murine P. aeruginosa respiratory infection model. The results 
support further evaluation of AMINOPIP2-ceftazidime 12 for P. aeruginosa lung infections in 
CF and broader study of ‘all-in-one’ C3Ds for other chronic infections.     
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 Bacterial biofilms are high-density populations of cells encapsulated within a self-
produced exo-polysaccharide matrix. The biofilm lifestyle protects many bacteria from a range 
of harmful stressors, with biofilm-encased bacteria known to be up to 1000-fold more tolerant 
of antibiotics than their planktonic counterparts1 and less vulnerable to host immune defences.2 
It is estimated that more than 80% of all infections involve biofilms and they are thought to be 
the root cause of chronic infections, such as those occurring on medical indwelling devices, 
urinary tract infections, otitis media, endocarditis, diabetic wounds, bone and joint infections 
and more.3 In cystic fibrosis (CF), chronic Pseudomonas aeruginosa lung infections are the 
major cause of morbidity and mortality in adults.4 Few therapeutics effectively treat biofilm-
mediated chronic infections and the development of new drugs that directly address biofilms 
remains a major challenge in infection control.3 
Given appropriate cues, many bacteria can transition between the biofilm and 
planktonic growth modes via a coordinated dispersal event mediated by the second messenger 
dinucleotide cyclic-di-GMP.5 Accordingly, a promising antibiofilm strategy has emerged 
wherein agents are used to initiate biofilm dispersal and enable clearance of the more 
vulnerable planktonic cells by co-administered antibiotics and host immune defenses.6 Low 
concentrations of nitric oxide (NO, nM range) have been shown to signal biofim dispersal in a 
broad range of bacteria, including P. aeruginosa, Staphylococcus aureus and Escherichia coli, 
supporting use of NO-donor compounds (or NO gas)7 in combination with antibiotics as an 
antibiofilm treatment approach.8 While many compounds are known that spontaneously emit 
NO in neutral aqueous (physiological) solution,9 their use clinically against biofilms would be 
complicated by the need to direct NO to the infection site and the safety risks associated with 
systematic exposure of non-target host tissues to NO. These risks could potentially be mitigated 
by use of NO donor prodrugs that release NO upon reaction with bacteria-specific enzymes, 
thereby targeting NO exposure to biofilm infection sites. 
Cephalosporin antibiotics have been used for many decades to treat diverse bacterial 
infections.10 Their primary mechanism of action involves inhibition of penicillin binding 
proteins (PBPs), which catalyze a crucial peptidoglycan cross-linking step during cell wall 
synthesis.11 In Gram-positive bacteria, PBPs are generally located on the outer surface of the 
cytoplasmic membrane making them easily accessible to cephalosporins and other β-lactams.12 
In Gram-negative bacteria, -lactams must penetrate the outer membrane to reach PBPs.13 
Additionally, bacterial defence enzymes (e.g. β-lactamases) present in the periplasmic space 
can hydrolyze β-lactams, rendering the treatment of Gram-negative infections with -lactams 
more challenging.14 
Cephalosporin-3´-diazeniumdiolates (C3Ds) are a class of biofilm-targeted NO donor 
prodrugs that carry a chemically stable, O2-linked diazeniumdiolate at the cephalosporin 3´-
position.15,16 We originally designed C3Ds to undergo reaction with bacterial -lactamases, 
where ring opening of the -lactam causes release (via the known conjugate elimination 
mechanism)17 of an unstable diazeniumdiolate anion (NONOate) that spontaneously emits NO, 
triggering biofilm dispersal (Figure 1). In principal, targeting NO to biofilm infection sites in 
this drug-like C3D form could serve to both optimize the NO-mediated dispersal signal and 
limit systemic exposure of host tissues to NO. 
Our first generation of C3Ds incorporated the simple 7-aminoacyl side chain structures 
of early-generation cephalosporins to enhance -lactamase susceptibility.15 For example, 
PYRRO-cefaloram 1 derived from the 1st-generation cephalosporin cefaloram (CFL) carried 
the 7-phenacetyl group (Figure 2). Thus, although armed with the cephalosporanic acid 
scaffold, 1st-generation C3Ds were not designed to elicit direct -lactam/PBP-mediated 
antibacterial effects but rather serve as drug-like, -lactamase-triggered NO carriers capable of 
targeting NO to infection sites. Their use clinically would require co-administration with 
antibiotics to control released planktonic and remaining biofilm cells (Figure 1). In our original 
report, we showed that 1st-generation C3Ds act synergistically with ciprofloxacin and 
tobramycin against P. aeruginosa biofilms in vitro.16 We later showed that the combination of 
PYRRO-cefaloram 1 and azithromycin enhances the susceptibility of nontypeable 
Haemophilus influenza biofilms co-cultured on primary ciliated respiratory epithelial cells18 
and primary ciliary dyskinesia cells.19 More recently, we reported that combining a 1st-
generation C3D with colistin leads to almost complete eradication of ex-vivo P. aeruginosa 
biofilms grown from CF sputum isolates.20 
One limitation of 1st-generation C3Ds is that they could only be used against -
lactamase-producing bacteria. It is possible that a simpler, more effective and perhaps more 
general antibiofilm approach might be realized if C3Ds could be optimized to show increased 
-lactamase stability and enhanced reactivity towards PBPs. In theory PBP-mediated -lactam 
ring opening of the C3D in this case would be expected to kill a subpopulation of biofilm 
bacteria and at the same time release a diazeniumdiolate anion and NO (by the same mechanism 
as the -lactamase-triggered reaction), potentially initiating biofilm dispersal. -lactam-
mediated PBP inactivation (by the same C3D) could then additionally serve to control released 
planktonic cells (Figure 1). 
 
 
Figure 1. Proposed effects arising from 1st and 2nd generation C3Ds. 
 
Early support for this ‵all-in-one′ C3D concept was obtained using PYRRO-cefaloram 
1, which showed potent -lactam-mediated antibacterial activity (minimum inhibitory 
concentration, MIC = 900 nM) against planktonic cultures of a non--lactamase producing 
strain of Streptococcus pneumoniae.21 The parent antibiotic cefaloram containing a 3´-acetate 
group in place of the diazeniumdiolate (Figure 2) showed the same MIC, thus demonstrating 
that the presence of a diazeniumdiolate at the 3´-position of a cephalosporin is compatible with 
classical -lactam-mediated PBP inactivation and antibacterial effects. These results motivated 
the current study, which aimed to explore the ‘all-in-one’ C3D concept using P. aeruginosa 
CF clinical isolates and identify leads for further study as new agents for chronic respiratory 
infections in CF. 
‘All-in-one’ C3Ds for CF applications would require high reactivity towards P. 
aeruginosa PBPs and low susceptibility to -lactamases. For cephalosporins, these properties 
can be inferred from low MICs in liquid culture assays. Guided by these principles, we 
conceived a 2nd-generation of C3Ds containing 7-aminoacyl side chains corresponding to the 
7-oxyimino ether groups of later-generation, extended-spectrum cephalosporins (i.e. 
cefuroxime (CXM), ceftazidime (CAZ), cefotaxime (CTX)/ceftriaxone (CRO)/cefepime (FEP) 
and cefozopran (CZO), Figure 2); structures that had been optimized in past medicinal 
chemistry efforts to confer high PBP reactivity and increased -lactamase stability.11 Twelve 
C3Ds were synthesized and screened for direct antibacterial activity against a panel of P. 
aeruginosa CF clinical isolates, along with a panel of ESKAPE22  and other human pathogens. 
The most active compound to emerge from the screening, AMINOPIP2-ceftazidime 12, 
showed good stability against -lactamases and activity against other human pathogens, was 
able to reduce P. aeruginosa in vitro biofilms that were resistant to the parent antibiotic 
(ceftazidime) and showed efficacy equivalent to ceftazidime in an acute  murine P. aeruginosa 
respiratory infection model. 
 
Figure 2. Compounds used in this study: (a) early generation cephalosporin antibiotics (b) 







The first series of analogs (PYRRO-C3Ds 3-6) carried the pyrrolidine-based 
diazeniumdiolate PYRRO/NO at the 3´-position. This NO donor appeared promising due to 
the rapid NO release properties of its anion (t1/2 = 2 s),
23 which we predict may be important in 
vivo as diffusion of an expelled diazeniumdiolate anion away from infection sites before 
releasing NO would presumably reduce effectiveness and elevate NO-mediated safety 
concerns. PYRRO-cefaloram 1 and PYRRO-cefalexin 2 were included as early-generation, 
non-oxyimino ether-containing C3D controls. 
Compound 1 was synthesised using our published procedure.15 For compounds 4-6, the 
requisite 2-aminothia(dia)zole carboxylic acid side chains were N-trityl protected using the 
known method (Scheme 1).24 The resulting carboxylic acids 16-18, along with the 
commercially available cephalexin and cefuroxime carboxylic acid intermediates 14 and 15, 
respectively, were coupled to the commercial 7-amino-p-methoxybenzyl (PMB)-protected 3′-
chloro-cephalosporin ester.HCl salt 13 using EDCI and DMAP. The acylation reactions were 
typically finished after 1 h and gave 3′-chloro-cephalosporin PMB esters 19-23 in good yields 
(63-85%) with minimal formation of the 2-isomer.25-27 
In situ Finkelstein conversion of chlorides 19-23 to iodides using NaI/acetone followed 
by substitution with PYRRO/NO sodium salt 24 gave the penultimate intermediates 25-29 in 
21-32% yields. Our reported method for PMB deprotection of C3Ds using neat 
TFA/anisole15,16 theoretically allowed for global deprotection of the Boc, PMB, trityl and tert-
butyl groups in all analogs. However, trial reactions using these conditions invariably produced 
complex mixtures. Based on work by Torii et al,28 we investigated varying concentrations of 
TFA in a phenol melt as a deprotection alternative. For deprotection of 26, where PMB was 
the only protecting group, molten phenol at 45 oC (without TFA) gave PYRRO-cefuroxime 3 
in 38% yield. Use of 40 molar equivalents of TFA in phenol afforded deprotection of the Boc, 
PMB and trityl groups of 25, 27 and 29, giving targets 2, 4 and 6 in 43, 54 and 36% yields, 
respectively. Use of 50 equivalents of TFA in molten phenol was required to remove the 
additional tert-butyl ester in 28, giving 5 in 31% yield. 
 
 
Scheme 1. Synthesis of PYRRO-C3Ds 2-6.  
 
 Computational analysis of over 180 diverse antibacterials by Hergenrother and co-
workers29 revealed that basic, positively charged non-sterically hindered primary amino groups 
can aid penetration of antibiotics into Gram-negative cells and increase activity. Based on this, 
a second series of C3Ds was designed to include the oxyimino ether side chains of cefepime 
and ceftazidime while carrying an additional primary amino group in the diazeniumdiolate 
moiety. Novel piperidine-based diazeniumdiolates (termed AMINOPIP/NO) were chosen for 
use due to their (predicted) short NO release half-lives and because non-chiral variants carrying 
1- and 2-carbon linked primary alkyl amines at the piperidine 4-position could be prepared 
from commercially available N-Boc-4-alkylamino piperidine precursors (30 and 31). The 
target C3Ds, termed AMINOPIP1- and AMINOPIP2-C3Ds (depending on the number of 
methylene groups in the 4-alkylamino chain), included two cefepime-based analogs 
(AMINOPIP1-cefepime 9 and AMINOPIP2-cefepime 10) and two ceftazidime-based analogs 
(AMINOPIP1-ceftazidime 11 and AMINOPIP2-ceftazidime 12). AMINOPIP1-cefaloram 7 
and AMINOPIP2-cefaloram 8 were prepared as 1st-generation (i.e. non-oxyimino ether-
containing) AMINOPIP-C3D controls (Scheme 2). 
To synthesize the required sodium diazeniumdiolate reagents 32 and 33, N-Boc-4-
alkylamino piperidines 30 and 31 were dissolved in MeOH/Et2O mixtures containing sodium 
methoxide in a Paar-Knorr vessel and exposed to NO gas at 50 psi. Shaking at room 
temperature for 48 h delivered N-Boc-AMINOPIP1/NO 32 and N-Boc-AMINOPIP2/NO 33 in 
90% and 93% yields, respectively (Scheme 2(a)).30 Reactions of 32 and 33 with protected 3′-
chloro-cephalosporin intermediates 21, 22 and 34 using the standard alkylation procedure (see 
above) gave the penultimate C3D precursors 35-40 in 23-46% yields (Scheme 2(b)). Stirring 
35 and 36 with 20 molar equivalents of TFA in molten phenol at 45 oC gave C3Ds 7 and 8 in 
73% and 81% yields, respectively. Deprotection of 37 and 38 with 40 equivalents of TFA 
afforded 9 and 10 in 52% and 46% yields, respectively. Use of 50 equivalents of TFA was 
required to remove the tert-butyl, N-trityl, PMB and Boc groups from 39 and 40, giving C3Ds 
11 and 12 in 39% and 33% yields, respectively. Complete synthetic chemistry details, 
compound characterization data and 1H and 13C NMR spectra are provided in the Supporting 
Information. All final compounds showed >95% purity, as determined by NMR and HPLC 
analyses. 
 
Scheme 2. Synthesis of: (a) sodium diazeniumdiolate reagents N-Boc-AMINOPIP1/NO 32 
and N-Boc-AMINOPIP2/NO 33 and (b) AMINOPIP-C3Ds 7-12. 
 
Antibacterial activity against P. aeruginosa Clinical Cystic Fibrosis Isolates 
 The antibacterial activities of C3Ds 1-12 and their parent cephalosporin antibiotic 
comparators were measured against P. aeruginosa reference strain PAO1 and ten clinical 
isolates obtained from the expectorated sputum of CF patients (see Supporting Information 
Table S1 for patient and strain information). The older cephalosporin antibiotics cefaloram 
(CFL) and cefalexin (CEX) showed no activity against any strain (MIC >128 g/mL) and 
introduction of PYRRO/NO or AMINOPIP1/NO diazeniumdiolates onto the CFL (i.e. 
compounds 1, 7 and 8) or CEX (i.e. compound 2) scaffolds did not improve activity 
(Supporting Information Table S2). Similarly, little or no activity was observed against any of 
the strains with the early oxyimino ether antibiotic cefuroxime (CXM) or its PYRRO/NO 
variant 3 (Table 1). Much greater activity was observed with cefozopran (CZO), which showed 
MICs mostly in the range 1-16 g/mL. However, introduction of the PYRRO/NO group onto 
the CZO scaffold (i.e. compound 6) caused a loss of potency in multiple strains. Cefepime 
(FEP) showed good activity across the panel (MIC = 0.5-16 g/mL) but again introduction of 
the PYRRO/NO 4, AMINOPIP1/NO 9 and AMINOPIP2/NO 10 diazeniumdiolates onto the 
FEP scaffold reduced potency. Similarly, ceftazidime (CAZ) was active against most strains 
but switching its 3′-pyridinium group to PYRRO/NO 5 reduced potency. In contrast, replacing 
the group with AMINOPIP1/NO and AMINOPIP2/NO diazeniumdiolates (compounds 11 and 
12) either maintained or improved potency (MIC = 0.5-16 g/mL) against PAO1 and nine out 
of the ten clinical strains (relative to CAZ). In general, the strain-specific activities of 11 and 
12 paralleled those of CAZ, where strains with higher resistance to CAZ also showed increased 
MICs against the C3Ds, but the losses in potency for the two C3Ds were lower (e.g. PA26 and 
PA37). 
 
Table 1. Minimum inhibitory concentration (MIC) of oxyimino ether cephalosporin antibiotics 
cefuroxime (CXM), cefozopran (CZO), cefepime (FEP) and ceftazidime (CAZ) and their C3D 
variants 3-6 and 9-12 against P. aeruginosa lab strain PAO1 and ten CF clinical isolates.  
MIC (g/mL) 
Strain CXM 3 CZO 6 FEP 4 9 10 CAZ  5 11 12 
PAO1 >128 >128 1 32 0.5 32 4 4 1 32 1 1 
PA05 64 >128 8 4 4 4 8 8 1 2 1 1 
PA10 128 >128 4 8 2 8 8 8 1 4 0.5 0.5 
PA21 >128 >128 8 128 4 >128 64 128 16 64 16 8 
PA26 >128 >128 16 >128 4 >128 32 128 64 >128 8 16 
PA30 >128 >128 8 >128 4 128 32 32 4 128 4 4 
PA37 >128 >128 16 16 4 32 16 32 128 >128 16 16 
PA44 >128 >128 >128 >128 16 128 128 128 4 128 16 16 
PA56 >128 >128 8 128 4 128 16 32 4 64 2 4 
PA58 >128 >128 4 128 8 >128 64 128 16 128 4 8 
PA68 >128 >128 8 >128 4 128 32 32 4 64 4 4 
 
 To inform structure-activity conclusions, the strains from the P. aeruginosa clinical 
isolate panel were characterised for -lactamase activity (relative to PAO1) using a nitrocefin 
assay.31 All strains tested positive for -lactamase activity, with PA5, PA30, PA44, PA56 and 
PA58 showing similar or slightly lower activity than PAO1 (Supporting Information Figure 
S1). Despite strains PA10, PA21, PA26, PA37 and PA58 all showing several-fold higher -
lactamase activity (than PAO1), these increases had only a small effect on the antibacterial 
potency of 11 and 12, suggesting the compounds show good stability against P. aeruginosa -
lactamases. 
 The -lactamase stability of C3Ds 1 and 4-12 was examined using our reported 
amperometric method15,16 with two commercial enzymes; one from the Gram-positive 
bacterium Bacillus cereus and one from P. aeruginosa. As this technique directly measures 
NO concentrations in solution, these assays additionally served to confirm NO release from the 
compounds following enzyme-mediated -lactam ring opening. 
 Addition to buffer solutions (PBS, pH 7.4) produced an immediate NO signal for some 
C3Ds, presumably due to a small amount of aqueous -lactam hydrolysis and accompanying 
diazeniumdiolate release occurring upon dissolution (Figure 3). Addition of the first aliquot of 
-lactamase produced a strong NO signal from susceptible C3Ds, reaching a plateau (steady-
state) several minutes later when the rates of NO production and loss become equal. Further 
increases in NO were observed after adding a second aliquot of -lactamase, indicating that 
exhaustion of C3D molecules had not occurred during the first -lactamase addition. 
As expected, 1st-generation C3D PYRRO-cefaloram 1 strongly released NO upon 
exposure to both B. cereus and P. aeruginosa -lactamases, thus providing a benchmark for 
stability comparisons (Figure 3a). Introduction of methoxyimino ether side chains (PYRRO-
cefepime 4 and PYRRO-cefozopran 6) significantly increased -lactamase stability (relative 
to 1), while addition of the 2-methyl propionic acid moiety (PYRRO-ceftazidime 5) afforded 
almost complete stability towards both enzymes. AMINOPIP2-cefaloram 8 underwent rapid 
hydrolysis in the presence of the B. cereus enzyme, while AMINOPIP1-cefaloram 7 and the 
AMINOPIP-cefepimes 9 and 10 were slightly more stable. Both AMINOPIP-ceftazidimes 11 
and 12 were completely stable in the presence of this enzyme. AMINOPIP-cefalorams 7 and 8 
were highly susceptible to the P. aeruginosa -lactamase but the four oxyimino ether 
AMINOPIP-C3Ds 9-12 all showed lower susceptibility. The generally higher -lactamase 
stability of ceftazidime-based C3Ds 5, 11 and 12 relative to other analogs aligns with the higher 
stability of ceftazidime compared to cephalosporins lacking the 2-methyl propionic acid 
oxyimino ether group.32  
 
 
Figure 3. (a) Stability of PYRRO-C3Ds 1, 4-6 in the presence of -lactamases from: (i) B. 
cereus and (ii) P. aeruginosa. (b) Stability of AMINOPIP-C3Ds 7-12 in the presence of -
lactamases from: (iii) B. cereus and (iv) P. aeruginosa. Arrows indicate addition of the 
following to a reaction vessel containing 20 mL PBS (pH 7.4) at 25 oC: a. C3Ds 1, 4-12 (final 
concentration 50 M), b. 100 L of 40 U.mL-1 B. cereus -lactamase or 25 L of 40 U.mL-1 
P. aeruginosa -lactamase. Multiple trials of each compound were performed and a 
representative curve is presented for each. 
 
Spectrum of antibacterial activity and eukaryotic cell cytotoxicity 
 C3Ds 1-12 were screened for activity against the major human pathogens E. coli, S. 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Enterococcus faecalis, 
Mycobacterium tuberculosis, Neisseria Gonorrhoeae and S. pneumoniae (Supporting 
Information Table S4). The MICs were obtained from multiple international laboratories using 
standard broth microdilution methods performed in accordance with the Clinical Laboratory 
Standards Institute (CLSI) guidelines.33 The MIC of the parent cephalosporin antibiotic was 
included for comparison, where available. 
 PYRRO-C3D controls 1 and 2 showed little or no activity against multiple E. coli 
strains and PYRRO-cefuroxime 3 showed similarly poor activity. Introduction of 
aminothi(dia)zole oxyimino ether side chains yielded a significant boost in potency, with 
PYRRO-cefepime 4, PYRRO-ceftazidime 5 and PYRRO-cefozopran 6 all showing much 
lower MICs than 1 and 2 against E. coli, including several below 1 g/mL. While 
AMINOPIP1-cefaloram 7 and AMINOPIP2-cefaloram 8 both showed poor activity, their 
oxyimino ether counterparts 9-12 showed good potency across most strains. In general, active 
C3Ds showed MICs similar to their parent cephalosporin antibiotics against E. coli. In the case 
of AMINOPIP1-ceftazidime 11, 8-16 fold higher activity was observed relative to ceftazidime. 
Collectively, these findings indicate that aminothia(dia)zole oxyimino ether side chains and 
AMINOPIP/NO donors confer C3Ds with the highest activity against E. coli. 
C3Ds 1-12 showed moderate potency (MIC ≤ 16 g/mL) against some strains of S. 
aureus and poor activity against others, with no clear structure-activity trends evident. For K. 
pneumoniae, all analogs were active against a strain that was sensitive to cephalosporin 
antibiotics (KP1). Oxyimino ether analogs 4-6 and 9-12 showed moderate potency against one 
other strain (KP3) but were poorly active against four others. Low potency was seen for all 
C3Ds against A. baumannii, consistent with the low activity of the parent cephalosporin 
antibiotics tested against this species. Six strains of E. faecalis were mostly resistant to C3Ds 
with the exception of AMINOPIP1-cefepime 9 and AMINOPIP2-cefepime 10, which showed 
good potency (MIC = 2 g/mL) against the EF1 strain. None of the compounds showed activity 
against M. tuberculosis. 
PYRRO-C3Ds 1-5 showed low activity against N. gonorrhoeae but the activity of 
PYRRO-cefozopran 6 was markedly higher (MIC = 1.25 g/mL). AMINOPIP-C3Ds 9-12 
were more active than their PYRRO-C3Ds variants and AMINOPIP2-ceftazidime 12 (MIC = 
0.6 g/mL) showed only 2-fold lower activity than ceftriaxone (CRO, MIC = 0.3 g/mL), the 
standard-of-care cephalosporin used to treat gonorrhoea.34 This represents a 67-fold increase 
in potency for AMINOPIP2-ceftazidime 12 relative to its parent antibiotic ceftazidime. The 
three S. pneumoniae strains tested were all highly sensitive to C3Ds, with AMINOPIP2-
cefepime 10 showing excellent potency (MIC = 0.06 g/mL). 
 C3Ds 1-12 were screened against seven additional P. aeruginosa lab strains held by the 
collaborating laboratories (Supporting Information Table S4). PYRRO-C3Ds 1-6 showed little 
or no activity across these strains and similarly poor activity was observed with AMINOPIP1-
cefaloram 7 and AMINOPIP2-cefaloram 8. Introduction of aminothiazole oxyimino ether side 
chains and AMINOPIP/NO diazeniumdiolates greatly enhanced activity, with AMINOPIP1-
cefepime 9, AMINOPIP2-cefepime 10, AMINOPIP1-ceftazidime 11 and AMINOPIP2-
ceftazidime 12 all showing equivalent or lower MICs than their parent antibiotics against some 
strains. In agreement with the clinical isolate testing (Table 1), AMINOPIP-ceftazidimes 11 
and 12 appeared as the most active C3Ds against P. aeruginosa, returning MICs in the range 
1-8 g/mL against four of the seven strains.  
 When tested for cytotoxicity in HEK293 cells, compounds 3-12 showed no evidence of 
growth inhibition at 32 g/mL (Supporting Information Table S5). AMINOPIP-ceftazidimes 
11 and 12 were also tested for haemolysis of human red blood cells and neither showed any 
effect at 32 g/mL. 
 
Activity of 12 against P. aeruginosa ex-vivo biofilms grown from cystic fibrosis clinical 
isolates 
 Having shown good antibacterial potency against the panel of P. aeruginosa clinical 
strains, broader activity against other human pathogens, good stability against -lactamases 
and low eukaryotic cell cytotoxicity, AMINOPIP2-ceftazidime 12 was advanced to testing 
against P. aeruginosa CF clinical isolate biofilms. Preliminary screening of the isolate panel 
using crystal violet assays35 led to selection of PA30 and PA68 for the experiments after 
confirming that they reproducibly form ex-vivo biofilms and their biofilms disperse in response 
to low micromolar concentrations of the spontaneous NO donor sodium nitroprusside (SNP, 
Supporting Information Figure S2). 
 Confocal laser scanning microscopy (CLSM) experiments were used to compare the 
effects of AMINOPIP2-ceftazidime 12 and its parent antibiotic (ceftazidime) on PA30 and 
PA68 biofilms. Biofilms were grown from the two strains in 35 mm glass-bottom microwell 
plates and treated with compounds. Following incubation, the supernatant was removed and 
the remaining biofilms treated with fluorescent dyes that label cells as living (SYTO9, green) 
or dead (propidium iodide, red). Fluorescence images were obtained and processed using 
COMSTAT software to characterize treated biofilms. 
 Treatment of PA30 biofilms with ceftazidime (128 g/mL) showed an unexpected 
effect, where statistically significant increases relative to untreated controls were observed in 
three out of four biofilm readouts (i.e. Total Biomass, Thickness Distribution and Total Surface 
Area Coverage but not Maximum Thickness; Figure 4(b)). No significant decreases were seen 
between controls and AMINOPIP2-ceftazidime 12 (128 g/mL), however, all four biofilm 
readouts were lower relative to ceftazidime. Treatment of PA68 biofilms with 12 (Figure 4(d)) 
yielded a greater dispersion effect, where statistically significant reductions were seen in all 
four readouts for 12 relative to controls, whereas no differences were observed for ceftazidime 
relative to controls. Significant reductions were also evident in all biofilm readouts for 12 




Figure 4. Activity of AMINOPIP2-ceftazidime 12 and ceftazidime (CAZ) against P. 
aeruginosa PA30 (a and b) and PA68 (c and d) biofilms. Biofilms were grown for 24 h and 
treated with compounds (128 g/mL, 3 h) before staining remaining biofilms with SYTO9 
(green; alive) and propidium iodide (red; dead). CLSM with COMSTAT analysis was 
performed to image and quantify: Total Biomass, Thickness Distribution, Maximum Thickness 
and Total Surface Area Coverage. Representative 3D CLSM images obtained after compound 
treatments are shown for: P. aeruginosa (a) PA30 and (c) PA68 biofilms. Error bars represent 
the mean ± SEM. One-way ANOVA with Tukey’s multiple comparisons test was used for 
statistical analysis comparing compound treatment groups to controls and to each other. ns = 
not significant; * = p < 0.05; ** = p <0.01; *** = p < 0.001. 
 
Activity of 12 in an acute murine P. aeruginosa respiratory infection model 
 The efficacy of AMINOPIP2-ceftazidime 12 was examined alongside ceftazidime in 
an acute P. aeruginosa lung infection model in neutropenic mice. In preparing for the model, 
a dose-escalation study was carried out (in mice) with 12 to investigate its tolerability. 
AMINOPIP2-ceftazidime 12 did not produce any adverse effects 30 minutes or 1 hour after a 
single subcutaneous (SC) injection of 50, 100 or 300 mg/kg (Supporting Information Table 
S6). All treated animals survived (Supporting Information Table S8) and showed no significant 
body weight changes over a 72 hour observation period (Supporting Information Table S7). 
 The pharmacokinetics of AMINOPIP2-ceftazidime 12 in mice were examined by 
monitoring concentrations of the drug in plasma and lung tissue homogenates over time 
following a single SC injection of 75 mg/kg. A mean peak plasma concentration of 104 g/mL 
was observed after 15 min, with levels lowering to 8 g/mL after 1 hour (Supporting 
Information Figure S3) and the compound still detectable in plasma after 6 hours (66 ng/mL). 
A peak lung concentration of 35 g/g was evident 15 min post-injection and after 1 hour the 
concentration was 4 g/g. At the 6 hour mark the lung concentration was 236 ng/g. 
Interestingly, the lung:plasma ratio remained steady (0.26-0.33) until 45 min after injection but 
rose dramatically after 1 hour (0.49) and increased further with time (2.0-4.5, Supporting 
Information Table S9), indicating 12 is cleared more slowly from the lungs than the plasma. 
 The MIC of ceftazidime and AMINOPIP2-ceftazidime 12 against the P. aeruginosa 
strain used in the infection model (FDA-CDC AR-BANK#0264) was measured at 1 g/mL 
and 4 g/mL, respectively, immediately prior to the experiment. Mice were inoculated 
intranasally with P. aeruginosa (9.1 × 105 CFU/mouse) and treatment commenced 2 hours 
later. Treatment consisted of subcutaneous injection of compounds at 50 mg/kg and 120 mg/kg 
every 4 hours for 24 hours (6 injections in total). The lungs were harvested and the bacterial 
burden measured. Two hours after inoculation the lung burden was 5.54 ± 0.12 log CFU/g in 
the vehicle control group, increasing to 9.50 ± 0.17 log CFU/g at the end of the 26 h period 
(Figure 5). Mice treated with 50 mg/kg ceftazidime showed a statistically significant reduction 
in lung bacteria at the end of the experiment (7.57 ± 0.39 log CFU/g) and the effect was 
increased at 120 mg/kg (6.40 ± 0.24 log CFU/g). Treatment with AMINOPIP2-ceftazidime 12 
also significantly reduced bacteria at 50 mg/kg (8.06 ± 0.21 log CFU/g) and 120 mg/kg (7.22 
± 0.23). No statistically significant difference was observed between ceftazidime and 
AMINOPIP2-ceftazidime 12 treated mice at either dose. 
 
 
Figure 5. Effects of ceftazidime (CAZ) and AMINOPIP2-ceftazidime 12 in an acute P. 
aeruginosa lung infection model in neutropenic mice. Animals were inoculated intranasally 
(0.02 mL/lung) with 9.1 x 105 CFU per mouse. Ceftazidime and AMINOPIP2-ceftazidime 12 
(50 and 120 mg/kg; n = 5 for each cohort) were administered SC every 4 hours starting 2 hours 
after infection. At 26 hours after inoculation, lung tissues were harvested and weighed and the 
lung bacterial burden measured (CFU/g). Error bars represent the mean ± SEM.  *Significant 
difference (p < 0.05) compared to the vehicle control was determined by one-way ANOVA 
followed by Dunnett’s test. ns = not significant. 
 
DISCUSSION AND CONCLUSIONS 
 In this study, we designed and synthesized a library of 2nd-generation C3Ds carrying 7-
aminoacyl side chain structures corresponding to the oxyimino ether groups of later generation 
cephalosporin antibiotics; cefuroxime, ceftazidime, cefepime and cefozopran. It was postulated 
that introduction of these groups, which had previously been optimized during historical 
medicinal chemistry campaigns, would confer C3Ds with increased -lactamase stability and 
high PBP reactivity, and therefore potentially broad spectrum antibacterial activity. We posited 
that reaction of the new C3Ds with PBPs might not only kill biofilm bacteria but also trigger 
dispersal of remaining biofilm cells due to the resulting NO signal. If the same molecule were 
then also able to kill released planktonic cells, C3Ds could represent ‘all-in-one’ antibiofilm 
antibiotics for use in chronic infections. 
 P. aeruginosa was the primary organism of interest as it is the cause of chronic 
respiratory infections in CF; the most well-studied of all biofilm-mediated chronic infections 
and logical target indication for C3D clinical development. Testing of the library against a 
panel of P. aeruginosa CF clinical isolates showed that oxyimino ether side chains alone are 
not sufficient to confer C3Ds with good antibacterial potency against P. aeruginosa since 
PYRRO-cefepime 4, PYRRO-ceftazidime 5 and PYRRO-cefozopran 6 all showed 
significantly reduced potency relative to their parent cephalosporin controls. While PYRRO-
ceftazidime 5 showed excellent stability towards-lactamases (Figure 3), this did not translate 
into potent antibacterial activity across the panel. We speculated that poor penetration of C3Ds 
across Gram-negative cell walls might instead be responsible. Based on Hergenrother and co-
workers study showing that positively charged, non-sterically hindered primary amino groups 
can aid antibiotic penetration across Gram-negative cell walls,29 we added amines to C3Ds by 
replacing the PYRRO/NO diazeniumdiolates at the 3′-position with AMINOPIP/NO donors. 
Switching to this group on cefaloram (AMINOPIP-cefalorams 7 and 8) had no effect as both 
compounds, like PYRRO-cefaloram 1, were totally inactive across the panel. Given that all of 
the P. aeruginosa clinical isolates expressed -lactamase activity (Supporting Information 
Figure S1) and compounds 1, 7, and 8 showed high -lactamase susceptibility (Figure 3), it is 
likely their poor activity was due to -lactamase degradation. Although NO would be expected 
to be released from these compounds after reactions with -lactamases, our previous work with 
S. pneumoniae suggests that NO delivered from C3Ds is unlikely to generate a direct 
antibacterial effect.21  
 AMINOPIP-C3Ds 9 and 10 containing the aminothiazole methoxyimino ether side 
chain of cefepime showed slightly better activity across the panel than their matched PYRRO-
C3D counterpart 4, but they showed poor activity relative to cefepime. In contrast, 
AMINOPIP1-ceftazidime 11 and AMINOPIP2-cetazidime 12 both showed much greater 
activity than PYRRO-ceftazidime 5, along with superior activity to the parent ceftazidime. We 
conclude that potent antibacterial activity in 2nd-generation C3Ds against P. aeruginosa 
requires a suitable balance between PBP reactivity, -lactamase susceptibility and cell wall 
penetration, with these parameters appearing to converge in structures 11 and 12. 
 Spectrum of activity testing revealed excellent potency for many of the C3Ds against 
E. coli and S. pneumoniae. This, along with the proven capacity of NO to disperse E. coli 
biofilms,36 motivates further exploration of C3Ds as possible treatments for chronic E. coli 
(e.g. urinary tract) infections. We previously reported that despite showing good antibacterial 
potency against S. pneumoniae, 1st-generation C3Ds alone are unable to disperse S. 
pneumoniae biofilms.21 This was in agreement with a separate report showing that NO 
modulates metabolic activity, but not dispersal, in S. pneumoniae biofilms.37 Thus, further 
exploration of 2nd-generation C3Ds against S. pneumoniae biofilms would appear to not be 
warranted. AMINOPIP2-ceftazidime 12 showed excellent activity against N. gonorrhoeae 
(MIC = 0.6 g/mL), suggesting further study of C3Ds against biofilms and chronic infections 
caused by this organism might yield interesting findings. Recent evidence showing that N. 
gonorrhoeae aggregates (similar to biofilms) are more resistant to ceftriaxone than planktonic 
cells,38 along with knowledge that NO plays a role in N. gonorrhoeae biofilm biology,39 support 
these studies. 
 To advance the ‘all-in-one’ hypothesis in P. aeruginosa, we tested the most active C3D 
AMINOPIP2-ceftazidime 12 for in vitro antibiofilm effects alongside ceftazidime. Preliminary 
screening of the P. aeruginosa clinical isolate panel for reproducible biofilm growth and the 
ability to undergo NO-mediated biofilm dispersal identified two strains suitable for the 
experiments, PA30 and PA68. Compound 12 showed the same MIC as ceftazidime against 
both strains (4 g/mL) but only 12 produced statistically significant biofilm reductions in the 
PA68 strain relative to untreated controls. Ceftazidime was indeed found to enhance biofilm 
growth in the PA30 strain. Together, these results suggest that NO released from 12 after 
reaction with PBPs might be responsible for the biofilm reduction, which would support the 
‘all-in-one’ C3D concept in P. aeruginosa. However, further experiments are required to 
conclusively demonstrate this.  
 To complete the study, we tested AMINOPIP2-ceftazidime 12 alongside ceftazidime 
in an acute P. aeruginosa respiratory infection model. Lead up experiments supported the 
safety of 12, where no signs of eukaryotic cell cytotoxicity were evident at 32 g/mL and no 
adverse effects, deaths or weight loss were observed in mice following SC administration at 
high dose (300 mg/kg). Pharmacokinetic studies revealed that the plasma levels of 12 in mice 
remained above 10 g/mL for about 1 h post-SC dosing at 75 mg/kg, while the levels in lung 
homogenates remained above 10 g/g for around 45 min. In terms of treating a respiratory 
infection, a positive feature was noted where clearance of 12 from the lung was found to be 
slower than the plasma. Based on these experiments, P. aeruginosa-infected mice were dosed 
with 12 at 50 and 120 mg/kg SC every 4 h for 24 h. Despite AMINOPIP2-ceftazidime 12 
showing 4-fold lower in vitro antibacterial potency against the P. aeruginosa strain used in the 
model, 12 was able to deliver reductions in bacterial lung burden that were equivalent 
toceftazidime. While not a chronic or biofilm infection model, this finding demonstrates that 
C3Ds can produce in vivo efficacy equivalent to a standard-of-care antipseudomonal 
cephalosporin. Collectively, results from this study support further evaluation of 12 as a 
potential new antipseudomonal for chronic lung infections in CF and motivate broader study 
of ‘all-in-one’ C3Ds against other chronic infections.  
 
METHODS 
Chemistry - General 
Carboxylic acids 14 and 15 were purchased from Sigma Aldrich. Carboxylic acid 16 
was prepared by N-tritylation of the commercially available aminothiazole precursor (Sigma 
Aldrich),40 as were 17 and 18 (AK Scientific).41 Cephalosporin hydrochloride salt 13 was 
purchased from AK Scientific. Sodium iodide, EDCI, trityl chloride and phenol were purchased 
from Sigma Aldrich. TFA was purchased from Auspep. DMAP was purchased from Alfa-
Aesar. Piperidines 30 and 31 were purchased from Combi-Blocks. Nitric oxide gas was 
purchased from Asia Pacific Gas Enterprise Company Ltd. Anhydrous acetone was prepared 
by heating analytical reagent (AR) grade solvent at reflux overnight with Drierite granules 
(anhydrous CaSO4) before distilling onto 4Å molecular sieves (pre-dried overnight at 400 
oC) 
under N2. Anhydrous methanol was prepared by distilling analytical reagent (AR) grade solvent 
onto 3Å molecular sieves (pre-dried overnight at 400 oC) under N2. Anhydrous ether was 
prepared by distillation from sodium/benzophenone ketyl. The term petroleum spirit (pet. 
spirit) refers to petroleum spirit within the boiling range 40-60 oC. Analytical thin layer 
chromatography (TLC) was performed using SiliaPlate Aluminium Backed F254, 200 m plates 
and SiliaPlate Aluminium Backed C18 F254, 150 m plates from Silicycle. Normal phase 
column chromatography was performed using SiliaFlash P60, 40-63 m, 230-400 mesh silica 
gel. Reverse phase column chromatography was performed using SiliaBond C18 (carbon 17 
%), 60 Å, 40-63 m, 230-400 mesh silica gel from Silicycle. Centrifugation was performed 
using a REMI R-8C BL centrifuge. 1H and 13C NMR spectra were recorded on Bruker 400 and 
500 MHz spectrometers. Chemical shifts () are relative to tetramethylsilane (TMS, 0 ppm). 
High resolution electrospray mass spectra were recorded on a Waters XEVO Ultima 
spectrometer. The final target compounds were lyophilised using a CHRIST Alpha 1-2 LD 
freeze dryer at -53 oC and 0.15 mbar. Compound 1 was prepared according to the reported 
method.15 
 
General Procedure I (Compounds 19-23) 
To a stirred solution of 14-18 (1 eq.), 13 (1 eq.) and 4-N,N-dimethylaminopyridine 
(DMAP) (0.5 eq.) in CH2Cl2 (15 mL) at 0 
oC was added 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) (1.1 eq.) in small portions and the resulting 
mixture was stirred for 1 h. The reaction mixture was diluted with CH2Cl2 (150 mL) and washed 
with water (100 mL) and brine (50 mL). The organic fraction was dried over anhydrous 
MgSO4, filtered and evaporated to give a yellow residue that was purified by silica gel column 




Compound 19 was prepared using General Procedure I from 14 (2.00 g, 7.96 mmol), 
13 (3.23 g, 7.96 mmol), EDCI (1.36 g, 8.76 mmol) and DMAP (0.486 g, 3.98 mmol) to give 
19 as a pale yellow solid (4.07 g, 85%). 1H NMR (CDCl3, 400 MHz)  7.36-7.30 (m, 7H), 6.89 
(d, 2H, J = 8.7 Hz), 6.74 (bs, 1H), 5.80 (dd, 1H, J = 9.2 Hz, J = 4.9 Hz), 5.66 (d, 1H, J = 6.2 
Hz), 5.24-5.21 (m, 1H, overlapped), 5.23 (d, 1H, J = 11.8 Hz), 5.18 (d, 1H, J = 11.8 Hz), 4.89 
(d, 1H, J = 4.9 Hz), 4.48 (d, 1H, J = 11.8 Hz), 4.37 (d, 1H, J = 11.8 Hz), 3.80 (s, 3H), 3.53 (d, 
1H, J = 18.3 Hz), 3.35 (d, 1H, J = 18.3 Hz), 1.41 (s, 9H). 13C NMR (CDCl3, 100 MHz)  170.7, 
164.2, 161.0, 160.0, 154.9, 137.3, 130.7, 129.2, 128.7, 127.4, 126.6, 126.1, 125.6, 114.0, 80.5, 




Compound 20 was prepared using General Procedure I from 15 (2.00 g, 11.8 mmol), 
13 (4.79 g, 11.8 mmol), EDCI (2.02 g, 13.0 mmol) and DMAP (0.722 g, 5.91 mmol) to give 
20 as a pale yellow solid (5.10 g, 83%). 1H NMR (CDCl3, 500 MHz)  7.60 (d, 1H, J = 1.9 
Hz), 7.40 (d, 2H, J = 8.4 Hz), 7.21 (d, 1H, J = 8.9 Hz), 6.95 (m, 3H), 6.50 (dd, 1H, J = 3.50 
Hz, J = 1.5 Hz), 5.95 (dd, 1H, J = 8.9 Hz, J = 5.0 Hz), 5.25 (d, 1H, J = 12.5 Hz), 5.22 (d, 1H, 
J = 12.5 Hz), 5.06 (d, 1H, J = 5.0 Hz), 4.54 (d, 1H, J = 11.8 Hz), 4.45 (d, 1H, J  = 11.8 Hz), 
4.10 (s, 3H), 3.82 (s, 3H), 3.68 (d, 1H, J = 18.3 Hz), 3.51 (d, 1H, J = 18.3 Hz).13C NMR (CDCl3, 
125 MHz)  163.4, 161.6, 160.2, 160.1, 145.4, 144.8, 142.5, 130.8, 126.6, 126.1, 125.8, 114.9, 
114.1, 111.9, 68.4, 63.7, 59.1, 57.5, 55.3, 43.2, 27.4. ESI-HRMS calcd. for 520.0940 [M+H]+ 




Compound 21 was prepared using General Procedure I from 16 (2.00 g, 4.51 mmol), 
13 (1.83 g, 4.51 mmol), EDCI (0.770 g, 4.96 mmol) and DMAP (0.275 g, 2.25 mmol) to give 
21 as a pale yellow solid (3.01 g, 84%). 1H NMR (CDCl3, 400 MHz)  7.34-7.27 (m, 17H), 
7.04 (s, 1H), 6.91-6.87 (m, 3H), 6.67 (s, 1H), 5.91 (dd, 1H, J = 8.9 Hz, J = 4.9 Hz), 5.23 (d, 
1H, J = 11.8 Hz), 5.19 (d, 1H, J = 11.8 Hz), 5.02 (d, 1H, J = 5.0 Hz), 4.54 (d, 1H, J = 11.8 Hz), 
4.42 (d, 1H J = 11.8 Hz), 4.06 (s, 3H), 3.80 (s, 3H), 3.64 (d, 1H, J = 18.4 Hz), 3.46 (d, 1H, J = 
18.3 Hz). 13C NMR (CDCl3, 100 MHz)  168.6, 163.9, 162.3, 161.1, 160.1, 147.2, 143.2, 140.1, 






Compound 22 was prepared using General Procedure I from 17 (2.00 g, 3.50 mmol), 
13 (1.42 g, 3.50 mmol), EDCI (0.597 g, 3.84 mmol) and DMAP (0.214 g, 1.75 mmol) to give 
22 as a pale yellow solid (2.52 g, 78%). 1H NMR (CDCl3, 500 MHz)  8.21 (d, 1H, J = 9.0 
Hz), 7.26-7.35 (m, 18H), 6.89 (d, 2H, J = 8.5 Hz), 6.72 (s, 1H), 5.98 (dd, 1H, J = 8.8 Hz, 5.0 
Hz), 5.26 (d, 1H, J = 12.0 Hz), 5.19 (d, 1H, J = 12.0 Hz), 5.02 (d, 1H, J = 5.0 Hz), 4.53 (d, 1H, 
J = 11.5 Hz), 4.44 (d, 1H, J = 11.5 Hz), 3.81 (s, 3H), 3.61 (d, 1H, J = 18.0 Hz), 3.44 (d, 1H, J 
= 18.0 Hz), 1.63 (s, 3H), 1.59 (s, 3H), 1.41 (s, 9H). 13C NMR (CDCl3, 125 MHz)  174.2, 
168.2, 164.2, 163.4, 161.3, 160.0, 149.3, 143.3, 141.5, 130.8, 129.4, 128.3, 127.7, 126.8, 126.3, 




Compound 23 was prepared using General Procedure I from 18 (2.00 g, 4.50 mmol), 
13 (1.82 g, 4.50 mmol), EDCI (0.768 g, 4.95 mmol) and DMAP (0.275 g, 2.25 mmol) to give 
23 as a pale yellow solid (2.25 g, 63%). 1H NMR (CDCl3, 400 MHz)  7.64 (s, 1H), 7.34-7.21 
(m, 18H), 6.88 (d, 2H, J = 8.7 Hz), 5.94 (dd, 1H, J = 8.8 Hz, J = 4.9 Hz), 5.23 (d, 1H, J = 11.8 
Hz), 5.18 (d, 1H, J = 11.8 Hz), 5.03 (d, 1H, J = 4.9 Hz), 4.52 (d, 1H, J = 11.9 Hz), 4.43 (d, 1H, 
J = 11.8 Hz), 4.12 (s, 3H), 3.80 (s, 3H), 3.63 (d, 1H, J = 18.4 Hz), 3.46 (d, 1H, J = 18.3 Hz). 
13C NMR (CDCl3, 100 MHz)  184.1, 163.9, 161.4, 161.2, 160.1, 160.0, 146.6, 142.1, 130.8, 
129.3, 128.7, 128.3, 126.7, 126.1, 125.8, 114.2, 72.4, 68.4, 64.0, 59.2, 57.9, 55.4, 43.4, 27.5. 
 
General Procedure II (Compounds 25-29, 35-40) 
Sodium iodide (1 eq.) was added to a suspension of PMB-protected cephalosporin ester 
19-23, 34 (1 eq.) in anhydrous acetone (10 mL) under argon and the mixture was stirred in the 
dark at room temperature for 1 h. Freshly prepared sodium diazeniumdiolates 24, 32, 33 (1 eq.) 
were added in one shot and the was mixture stirred at room temperature for a further 1.5 hrs. 
The solvent was removed under reduced pressure and the residue purified by silica gel column 




1-yl)diazene 1-oxide 25 
Compound 25 was prepared using General Procedure II from 19 (500 mg, 0.830 mmol), 
NaI (124 mg, 0.830 mmol) and 24 (127 mg, 0.830 mmol) to give 25 as a yellow solid (185 mg, 
32%). 1H NMR (CDCl3, 500 MHz)  7.39-7.30 (m, 7H), 6.88 (d, 2H, J = 8.5 Hz), 6.50 (bs, 
1H), 5.79 (dd, 1H, J = 9.2 Hz, J = 4.8 Hz), 5.59 (bs, 1H), 5.24-5.14 (m, 4H), 4.89-4.84 (m, 2H), 




yl)diazene 1-oxide 26 
Compound 26 was prepared using General Procedure II from 20 (500 mg, 0.961 mmol), 
NaI (144 mg, 0.961 mmol) and 24 (147 mg, 0.961 mmol) to give 26 as a yellow solid (165 mg, 
28%). 1H NMR (CDCl3, 500 MHz)  7.51 (d, 1H, J = 1.7 Hz), 7.35 (d, 2H, J = 8.3 Hz), 7.20 
(d, 1H, J = 9.0 Hz), 6.91-6.89 (m, 3H), 6.48 (dd, 1H, J = 3.5 Hz, J = 1.8 Hz), 5.95 (dd, 1H, J = 
9.1 Hz, J = 5.0 Hz), 5.26-5.19 (m, 3H), 5.04 (d, 1H, J = 5.0 Hz), 4.93 (d, 1H, J = 14.1 Hz), 
4.09 (s, 3H), 3.82 (s, 3H), 3.68 (d, 1H, J = 18.6 Hz), 3.54-3.47 (m, 5H), 1.93 (t, 4H, J = 6.5 
Hz). 13C NMR (CDCl3, 125 MHz)  163.8, 161.3, 160.2, 160.0, 145.4, 144.8, 142.6, 130.7, 
127.1, 126.7, 125.5, 114.9, 114.0, 111.9, 71.4, 68.2, 63.7, 59.0, 57.3, 55.3, 50.8, 26.4, 22.8. 




(pyrrolidin-1-yl)diazene 1-oxide 27 
Compound 27 was prepared using General Procedure II from 21 (500 mg, 0.629 mmol), 
NaI (94 mg, 0.629 mmol) and 24 (96 mg, 0.629 mmol) to give 27 as a yellow solid (145 mg, 
26%). 1H NMR (CDCl3, 400 MHz)  7.34-7.27 (m, 17H), 7.01 (s, 1H), 6.89 (d, 2H, J = 8.7 
Hz), 6.78 (d, 1H, J = 9.0 Hz), 6.72 (s, 1H), 5.91 (dd, 1H, J = 9.0 Hz, J = 4.9 Hz), 5.25-5.16 (m, 
3H), 5.01 (d, 1H, J = 4.9 Hz), 4.91 (d, 1H, J = 14.1 Hz), 4.07 (s, 3H), 3.81 (s, 3H), 3.59 (d, 1H, 
J = 18.6 Hz), 3.50-3.45 (m, 5H), 1.94-1.90 (m, 4H). 13C NMR (CDCl3, 100 MHz)  168.6, 
163.8, 162.1, 161.3, 160.0, 147.1, 143.1, 140.8, 130.7, 129.3, 128.3, 127.7, 127.0, 126.7, 125.4, 
114.0, 113.2, 71.8, 71.4, 68.1, 63.3, 58.9, 57.4, 55.3, 50.8, 26.4, 22.9. ESI-HRMS calcd. for 




azabicyclo[4.2.0]oct-2-en-3-yl)methoxy)-1-(pyrrolidin-1-yl)diazene 1-oxide 28 
Compound 28 was prepared using General Procedure II from 22 (500 mg, 0.542 mmol), 
NaI (81 mg, 0.542 mmol) and 24 (83 mg, 0.542 mmol) to give 28 as a yellow solid (116 mg, 
21%). 1H NMR (CDCl3, 500 MHz)  8.13 (d, 1H, J = 9.5 Hz), 7.34-7.28 (m, 18H), 6.89 (d, 
2H, J = 8.0 Hz), 6.72 (s, 1H), 5.98 (dd, 1H, J = 8.5 Hz, J = 5.0 Hz), 5.27-5.24 (m, 2H), 5.17 
(d, 1H, J = 12.0 Hz), 5.00 (d, 1H, J = 5.0 Hz), 4.90 (d, 1H, J = 14.0 Hz), 3.81 (s, 3H), 3.55 (d, 
1H, J = 18.5 Hz), 3.49-3.43 (m, 5H), 1.92 (m, 4H), 1.63 (s, 3H), 1.59 (s, 3H), 1.41 (s, 9H). 13C 
NMR (CDCl3, 125 MHz)  174.0, 168.6, 164.2, 163.2, 161.6, 159.9, 148.9, 143.2, 141.2, 130.7, 
129.4, 128.2, 127.6, 127.2, 126.9, 125.6, 114.0, 112.5, 83.0, 82.1, 71.5, 68.0, 59.1, 57.7, 55.3, 
50.8, 28.0, 26.4, 24.2, 23.8, 22.9. ESI-HRMS calcd. for 1039.3453 [M+Na]+ 




(pyrrolidin-1-yl)diazene 1-oxide 29 
Compound 29 was prepared using General Procedure II from 23 (500 mg, 0.629 mmol), 
NaI (94 mg, 0.629 mmol) and 24 (96 mg, 0.629 mmol) to give 29 as a yellow solid (134 mg, 
24%). 1H NMR (CDCl3, 400 MHz)  7.60 (s, 1H), 7.34-7.22 (m, 18H), 6.88 (d, 2H, J = 8.7 
Hz), 6.81 (d, 1H, J = 8.7 Hz), 5.94 (dd, 1H, J = 8.9 Hz, J = 4.9 Hz), 5.24-5.14 (m, 3H), 5.01 
(d, 1H, 4.9 Hz), 4.91 (d, 1H, J = 14.0 Hz), 4.12 (s, 3H), 3.80 (s, 3H), 3.57 (d, 1H, J = 18.6 Hz), 
3.49-3.45 (m, 5H), 1.92 (t, 4H, J = 6.8 Hz). 13C NMR (CDCl3, 126 MHz)  184.1, 164.0, 161.5, 
161.3, 160.1, 160.0, 146.6, 142.0, 130.8, 129.3, 128.7, 128.4, 127.0, 126.9, 125.5, 114.1, 72.4, 
71.5, 68.2, 64.0, 59.3, 57.7, 55.4, 50.9, 26.5, 23.0. ESI-HRMS calcd. for 912.2568 [M+Na]+ 




yl)methoxy)diazene 1-oxide 35 
Compound 35 was prepared using General Procedure II from 34 (500 mg, 1.03 mmol), 
NaI (154 mg, 1.03 mmol) and 32 (304 mg, 1.03 mmol) to give 35 as an off white solid (342 
mg, 46%). 1H NMR (CDCl3, 500 MHz)  7.38-7.26 (m, 7H), 6.88 (d, 2H, J = 8.7 Hz), 6.19 (d, 
1H, J = 8.7 Hz), 5.82 (dd, 1H, J = 9.0 Hz, J = 4.9 Hz), 5.21-5.15 (m, 3H), 4.96 (d, 1H, J = 14.0 
Hz), 4.91 (d, 1H, J = 4.9 Hz), 4.62 (bs, 1H), 3.86 (d, 2H, J = 9.6 Hz), 3.80 (s, 3H), 3.67 (d, 1H, 
J = 16.0 Hz), 3.62 (d, 1H, J = 16.0 Hz), 3.49 (d, 1H, J = 18.5 Hz), 3.41 (d, 1H, J = 18.5 Hz), 
3.01 (t, 2H, J = 6.2 Hz), 2.84 (t, 2H, J = 12.0 Hz), 1.78 (d, 2H, J = 12.5 Hz), 1.65-1.55 (m, 1H, 
overlapped by H2O), 1.44 (s, 9H), 1.36 (t, 2H, J = 12.8 Hz).
13C NMR (CDCl3, 125 MHz)  
171.3, 164.8, 161.4, 160.1, 156.2, 133.8, 130.8, 129.6, 129.3, 127.9, 126.8, 126.4, 125.8, 114.1, 
79.6, 71.8, 68.3, 59.4, 57.7, 55.4, 51.4, 45.6, 43.4, 35.9, 28.6, 28.3, 26.2. ESI-HRMS calcd. for 




diazene 1-oxide 36 
Compound 36 was prepared using General Procedure II from 34 (500 mg, 1.03 mmol), 
NaI (154 mg, 1.03 mmol) and 33 (319 mg, 1.03 mmol) to give 36 as an off white solid (326 
mg, 43%). 1H NMR (CDCl3, 500 MHz)  7.36-7.25 (m, 7H), 6.89 (d, 2H, J = 8.7 Hz), 6.13 (d, 
1H, J = 9.1 Hz), 5.81 (dd, 1H, J = 9.1 Hz, J = 4.9 Hz), 5.24-5.10 (m, 3H), 4.93 (d, 1H, J = 14.1 
Hz), 4.90 (d, 1H, J = 4.9 Hz), 4.52 (bs, 1H), 3.84-3.76 (m, 5H),  3.66 (d, 1H, J = 16.1 Hz), 3.61 
(d, 1H, J = 16.1 Hz), 3.50 (d, 1H, J = 18.6 Hz), 3.40 (d, 1H, J = 18.6 Hz), 3.15 (d, 2H, J = 5.9 
Hz), 2.82 (t, 2H, J = 11.6 Hz), 1.82 (d, 2H, J = 10.8 Hz), 1.46-1.33 (m, 14H). 13C NMR (CDCl3, 
125 MHz)  171.1, 164.7, 161.3, 159.9, 156.0, 133.7, 130.7, 129.5, 129.2, 127.8, 126.7, 126.4, 
125.5, 114.0, 79.5, 71.7, 68.1, 59.2, 57.5, 55.3, 51.6, 43.3, 38.1, 36.1, 32.5, 30.7, 28.4, 26.1. 




azabicyclo[4.2.0]oct-2-en-3-yl)methoxy)diazene 1-oxide 37 
Compound 37 was prepared using General Procedure II from 21 (500 mg, 0.629 mmol), 
NaI (94 mg, 0.629 mmol) and 32 (187 mg, 0.629 mmol) to give 37 as a yellow solid (182 mg, 
28%).1H NMR (CDCl3, 500 MHz)  7.33-7.24 (m, 18H), 7.04 (bs, 1H), 6.89 (d, 2H, J = 8.7 
Hz), 6.68 (s, 1H), 5.90 (dd, 1H, J = 8.8 Hz , J = 4.9), 5.25-5.13 (m, 3H), 5.03-4.98 (m, 2H), 
4.65 (bs, 1H), 4.06 (s, 3H), 3.87 (d, 2H, J = 11.3 Hz), 3.81 (s, 3H), 3.54 (d, 1H, J = 18.5 Hz), 
3.46 (d, 1H, J = 18.4 Hz), 3.01 (t, 2H, J = 6.4 Hz), 2.85 (t, 2H, J  = 12.0 Hz), 1.78 (d, 2H, J  = 
10.5 Hz), 1.56 (bs, 1H), 1.41 (s, 9H),  1.40-1.32 (m, 2H). 13C NMR (CDCl3, 125 MHz)  168.7, 
163.9, 162.2, 161.4, 160.1, 156.1, 147.3, 143.2, 141.0, 130.8, 129.4, 128.4, 127.8, 126.8, 126.5, 
125.8, 114.2, 113.2, 79.6, 71.9, 71.7, 68.3, 63.4, 59.1, 57.6, 55.4, 51.4, 45.5, 35.9, 28.5, 28.3, 




azabicyclo[4.2.0]oct-2-en-3-yl)methoxy)diazene 1-oxide 38 
Compound 38 was prepared using General Procedure II from 21 (500 mg, 0.629 mmol), 
NaI (94 mg, 0.629 mmol) and 33 (195 mg, 0.629 mmol) to give 38 as a yellow solid (151 mg, 
23%). 1H NMR (CDCl3, 400 MHz)  7.34-7.28 (m, 17H), 7.03 (s, 1H), 6.89 (d, 2H, J = 8.7 
Hz), 6.84 (d, 1H, J = 8.9 Hz), 6.70 (s, 1H), 5.91 (dd, 1H, J = 9.0 Hz, J = 4.9 Hz), 5.27 (d, 1H, 
J = 14.0 Hz), 5.22 (d, 1H, J = 11.8 Hz), 5.17 (d, 1H, J = 11.8 Hz), 5.01 (d, 1H, J = 5.0 Hz), 
4.97 (d, 1H, J = 14.0 Hz), 4.50 (bs, 1H), 4.06 (s, 3H), 3.84-3.75 (m, 5H), 3.55 (d, 1H, J = 18.5 
Hz), 3.46 (d, 1H, J = 18.6 Hz), 3.15 (d, 2H, J = 5.9 Hz), 2.83 (t, 2H, J = 11.1 Hz), 1.82 (d, 2H, 
J = 10.2 Hz), 1.44-1.40 (m, 14H). 13C NMR (CDCl3, 100 MHz)  168.7, 163.9, 162.2, 161.4, 
160.1, 156.1, 147.2, 143.2, 141.0, 130.8, 129.4, 128.4, 127.8, 126.8, 126.6, 125.7, 114.2, 113.2, 
79.4, 71.9, 71.8, 68.3, 63.5, 59.1, 57.5, 55.4, 51.8, 38.2, 36.3, 32.6, 30.8, 28.5, 26.4. ESI-HRMS 





-1-yl)diazene 1-oxide 39 
Compound 39 was prepared using General Procedure II from 22 (500 mg, 0.542 mmol), 
NaI (81 mg, 0.542 mmol) and 32 (161 mg, 0.542 mmol) to give 39 as a yellow solid (195 mg, 
31%). 1H NMR (CDCl3, 500 MHz)  8.12 (d, 1H, J = 8.7 Hz), 7.34-7.26 (m, 17H), 6.91-6.88 
(m, 3H), 6.72 (s, 1H), 5.99 (dd, 1H, J = 8.8 Hz, J = 5.0 Hz), 5.29 (d, 1H, J = 14.0 Hz), 5.24 (d, 
1H, J = 11.8 Hz), 5.17 (d, 1H, J = 11.8 Hz), 5.00 (d, 1H, J = 5.0 Hz), 4.96 (d, 1H, J = 14.1 Hz), 
4.63 (bs, 1H), 3.86-3.81 (m, 5H), 3.52 (d, 1H, J = 18.5 Hz), 3.43 (d, 1H, J = 18.5 Hz), 3.03 (t, 
2H, J = 6.3 Hz), 2.84 (tt, 2H, J = 12.0 Hz, J = 2.6 Hz), 1.81 (d, 2H, J = 13.0 Hz), 1.62 (s, 3H), 
1.58 (s, 3H), 1.60-1.54 (m, 1H, overlapped), 1.44 (s, 9H), 1.41 (s, 9H). 1.41-1.36 (m, 2H, 
overlapped). 13C NMR (CDCl3, 125 MHz)  174.0, 168.2, 164.3, 163.4, 161.6, 160.0, 156.1, 
149.3, 143.3, 141.5, 130.8, 129.5, 128.4, 127.7, 126.9, 126.8, 125.9, 114.2, 112.6, 83.1, 82.2, 
79.6, 72.0, 68.2, 59.3, 57.8, 55.4, 51.5, 45.5, 35.9, 28.5, 28.4, 28.2, 26.5, 24.4, 23.9. ESI-HRMS 





piperidin-1-yl)diazene 1-oxide 40 
Compound 40 was prepared using General Procedure II from 22 (500 mg, 0.542 mmol), 
NaI (81 mg, 0.542 mmol) and 33 (168 mg, 0.542 mmol) to give 40 as a yellow solid (236 mg, 
37%). 1H NMR (CDCl3, 500 MHz)  8.11 (d, 1H, J = 8.8 Hz), 7.34-7.26 (m, 17H), 6.91-6.88 
(m, 3H), 6.72 (s, 1H), 5.99 (dd, 1H, J = 8.8 Hz, J = 5.0 Hz), 5.30 (d, 1H, J = 14.1 Hz), 5.24 (d, 
1H, J = 11.8 Hz), 5.17 (d, 1H, J = 11.8 Hz), 5.00 (d, 1H, J = 5.0 Hz), 4.95 (d, 1H, J = 14.1 Hz), 
4.49 (bs, 1H), 3.83-3.78 (m, 5H), 3.52 (d, 1H, J = 18.4 Hz), 3.43 (d, 1H, J = 18.5 Hz), 3.16 (d, 
2H, J = 5.9 Hz), 2.83 (tt, 2H, J = 11.6 Hz, J = 2.7 Hz), 1.82 (d, 2H, J = 10.0 Hz), 1.62 (s, 3H), 
1.58 (s, 3H), 1.48-1.44 (m, 2H, overlapped, observed in gHSQC), 1.45-1.41 (m, 1H, 
overlapped, observed in gHSQC), 1.44-1.38 (m, 2H, overlapped, observed in gHSQC), 1.44 
(s, 9H), 1.41 (s, 9H). 13C NMR (CDCl3, 125 MHz)  174.1, 168.3, 164.3, 163.4, 161.7, 160.1, 
156.1, 149.3, 143.4, 141.5, 130.9, 129.5, 128.4, 127.7, 127.0, 126.8, 125.8, 114.2, 112.6, 83.1, 
82.2, 79.4, 72.0, 68.2, 59.3, 57.8, 55.4, 51.8, 38.2, 36.3, 32.6, 30.8, 28.6, 28.2, 26.5, 24.4, 23.9. 
ESI-HRMS calcd. for 1174.4742 [M+H]+ C60H72O12N9S2, found 1174.4760. 
 
General Procedure III (Compounds 2-12) 
Mixtures containing 25-29, 35-40 (1 eq.) and phenol (3-4 g) were heated to 45 oC in a 
dry flask under an atmosphere of argon. Upon complete melting of phenol, trifluoroacetic acid 
(0-50 eq.) was added and the mixtures stirred at 45 oC for 2.5 hrs. Addition of 50% 
pet.spirit/ether (100 mL) to the cooled reaction mixtures (room temperature) caused 
precipitation of a white solid that was collected by centrifugation (3000 rpm, 5 min). The pellets 
were washed with ice cold anhydrous diethyl ether and the crude solid was purified by C18-
reverse phase silica gel column chromatography. Fractions containing the pure product (as 
indicated by C18-reverse phase silica gel TLC) were combined and lyophilised. 
 
(Z)-2-((7-((R)-2-amino-2-phenylacetamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-
2-en-3-yl)methoxy)-1-(pyrrolidin-1-yl)diazene 1-oxide (PYRRO-cefalexin 2) 
Compound 2 was prepared using General Procedure III from 25 (200 mg, 0.287 mmol) 
and TFA (879 L, 11.5 mmol) to give 2 as a fluffy white solid (59 mg, 43%). 1H NMR (CD3OD, 
400 MHz)  7.54-7.52 (m, 2H), 7.47-7.44 (m, 3H), 5.73 (d, 1H, J = 4.8 Hz), 5.20 (d, 1H, J = 
12.5 Hz), 5.05 (s, 1H), 4.96 (d, 1H, J = 4.8 Hz), 4.81-4.79 (m, 1H, overlapped by H2O, observed 
in gHSQC), 3.51-3.46 (m, 5H), 3.24 (d, 1H, J = 17.7 Hz), 1.94-1.91 (m, 4H). 13C NMR 
(CD3OD, 100 MHz)  169.7, 168.3, 164.6, 134.3, 133.8, 131.1, 130.4, 129.5, 117.8, 73.9, 60.2, 






Compound 3 was prepared using General Procedure III from 26 (200 mg, 0.325 mmol) 
to give 2 as a fluffy white solid (61 mg, 38%). No TFA was required. 1H NMR (CD3OD, 500 
MHz)  7.64 (s, 1H), 6.76 (d, 1H, J = 3.4 Hz), 6.56 (dd, 1H, J = 3.5 Hz, J = 1.8 Hz), 5.86 (d, 
1H, J = 4.8 Hz), 5.24 (d, 1H, J = 13.2 Hz), 5.18 (d, 1H, J = 4.8 Hz), 4.94 (d, 1H, J = 13.2 Hz), 
3.97 (s, 3H), 3.68 (d, 1H, J = 18.1 Hz), 3.53-3.51 (m, 5H), 1.95 (m, 4H). 13C NMR (CD3OD, 
125 MHz)  165.0, 164.4, 147.1, 146.2, 146.1, 128.6 (observed in gHMBC), 123.2 (observed 
in gHMBC), 114.1, 112.8, 73.1, 63.2, 58.9, 51.9, 27.2, 23.7. ESI-HRMS calcd. for 517.1112 





Compound 4 was prepared using General Procedure III from 27 (200 mg, 0.225 mmol) 
and TFA (689 L, 9.0 mmol) to give 4 as a fluffy white solid (64 mg, 54%).  1H NMR (DMSO-
d6, 400 MHz)  9.58 (d, 1H, 8.2 Hz), 7.22 (s, 2H), 6.73 (s, 1H), 5.72 (dd, 1H, J = 4.76 Hz, J = 
8.1 Hz), 5.12 (d, 1H, J = 5.0 Hz), 5.09 (d, 1H, J = 13.3 Hz), 4.80 (d, 1H, J = 12.4 Hz), 3.83 (s, 
3H), 3.54 (d, 1H, J = 17.8 Hz), 3.44-3.40 (m, 5H), 1.85 (t, 4H, J = 6.6 Hz). 13C NMR (DMSO-
d6, 100 MHz)  168.4, 163.2, 163.1, 163.0, 149.0, 142.6, 130.4 (observed in gHMBC), 119.7 
(observed in gHMBC), 108.9, 71.6, 61.9, 58.4, 57.6, 50.5, 25.9, 22.2. ESI-HRMS calcd. for 




1-yl)diazene 1-oxide (PYRRO-ceftazidime 5) 
Compound 5 was prepared using General Procedure III from 28 (200 mg, 0.197 mmol) 
and TFA (752 L, 9.8 mmol) to give 5 as a fluffy white solid (37 mg, 31%). 1H NMR (DMSO-
d6, 500 MHz)  7.29 (s, 2H), 6.72 (s, 1H), 5.85 (dd, 1H, J = 8.2 Hz, J = 4.8 Hz), 5.20 (d, 1H, J 
= 4.8 Hz), 5.03 (d, 1H, J  = 12.7 Hz), 4.82 (d, 1H, J  = 12.7 Hz), 3.60 (d, 1H, J = 18.0 Hz), 3.52 
(d, 1H, J  = 18.0 Hz), 3.44-3.39 (m, 4H), 1.87-1.83 (m, 4H), 1.45 (s, 3H), 1.44 (s, 3H). 13C 
NMR (DMSO-d6, 125 MHz)  175.0, 168.5, 164.0, 162.9, 149.3, 142.6, 127.2, 123.2, 109.8, 
81.7, 70.9, 58.6, 57.6, 50.5, 26.1, 24.2, 23.8, 22.3. ESI-HRMS calcd. for 597.1191 [M-H]- 





Compound 6 was prepared using General Procedure III from 29 (200 mg, 0.225 mmol) 
and TFA (688 L, 9.0 mmol) to give 6 as a fluffy white solid (43 mg, 36%). 1H NMR (DMSO-
d6, 400 MHz)  9.56 (d, 1H, J = 8.6 Hz), 8.13 (s, 2H), 5.77 (dd, 1H, J = 8.5 Hz, J = 4.8 Hz), 
5.12 (d, 1H, J = 4.8 Hz), 5.07 (d, 1H, J = 12.5 Hz), 4.80 (d, 1H, J = 12.5 Hz), 3.91 (s, 3H), 3.55 
(d, 1H, J = 17.8 Hz), 3.47-3.33 (m 5H, overlapped by H2O), 1.85 (t, 4H, J = 6.5 Hz). 
13C NMR 
(DMSO-d6, 100 MHz)  183.2, 163.5, 163.1, 162.0, 162.0, 148.1, 129.7 (observed in gHMBC), 
120.2 (observed in gHMBC), 71.4, 62.5, 58.3, 57.5, 50.5, 25.9, 22.3. ESI-HRMS calcd. for 
526.0933 [M-H]- C17H20O7N9S2, found 526.0927. 
 
(Z)-1-(4-(aminomethyl)piperidin-1-yl)-2-((2-carboxy-8-oxo-7-(2-phenylacetamido)-5-thia-1-
azabicyclo[4.2.0]oct-2-en-3-yl)methoxy)diazene 1-oxide (AMINOPIP1-cefaloram 7) 
Compound 7 was prepared using General Procedure III from 35 (200 mg, 0.276 mmol) 
and TFA (422 L, 5.5 mmol) to give 7 as a fluffy white solid (102 mg, 73%). 1H NMR (DMSO-
d6, 400 MHz)  9.03 (d, 1H, J = 8.4 Hz), 8.48 (bs, 2H), 7.31-7.20 (m, 5H), 5.54 (dd, 1H, J = 
8.4 Hz, J = 4.8 Hz), 5.25 (d, 1H, J = 11.7 Hz), 4.98 (d, 1H, J = 4.9 Hz), 4.77 (d, 1H, J = 11.7 
Hz), 3.76 (t, 2H, J = 12.2 Hz), 3.58 (d, 1H, J = 13.9 Hz), 3.50 (d, 1H, J = 14.0 Hz), 3.45 (d, 
1H, J = 17.4 Hz), 3.30 (d, 1H, J = 17.5 Hz), 2.88-2.78 (m, 2H), 2.76-2.67 (m, 2H), 1.84 (d, 2H, 
J = 13.2 Hz), 1.80-1.70 (m, 1H), 1.40-1.24 (m, 2H). 13C NMR (DMSO-d6, 100 MHz)  171.0, 
164.3, 163.3, 135.9, 134.7, 129.0, 128.2, 126.4, 112.2 (observed in HMBC), 73.0, 58.6, 57.4, 
50.25, 50.17, 42.9, 41.6, 32.8, 27.4, 27.3 25.5. ESI-HRMS calcd. for 505.1864 [M+H]+ 
C22H29N6O6S, found 505.1886. 
 
(Z)-1-(4-(2-aminoethyl)piperidin-1-yl)-2-((2-carboxy-8-oxo-7-(2-phenylacetamido)-5-thia-1-
azabicyclo[4.2.0]oct-2-en-3-yl)methoxy)diazene 1-oxide (AMINOPIP2-cefaloram 8) 
Compound 8 was prepared using General Procedure III from 36 (200 mg, 0.271 mmol) 
and TFA (414 L, 5.4 mmol) to give 8 as a fluffy white solid (114 mg, 81%). 1H NMR (DMSO-
d6, 500 MHz)  9.02 (d, 1H, J = 8.6 Hz), 8.24 (bs, 2H), 7.30-7.20 (m, 5H), 5.53 (d, 1H, J =9.2 
Hz), 5.23 (d, 1H, J = 10.1 Hz), 4.97 (s, 1H), 4.80 (d, 1H, J = 10.2 Hz). 13C NMR (DMSO-d6, 
126 MHz)  171.0, 164.0, 163.3, 136.0, 134.6 (observed in gHMBC) 129.0, 128.2, 126.4, 112.5 
(observed in gHMBC) 73.0, 58.6, 57.4, 50.9, 41.6, 36.4, 32.9, 31.5, 29.9, 25.4. ESI-HRMS 




oxide (AMINOPIP1-cefepime 9) 
Compound 9 was prepared using General Procedure III from 37 (200 mg, 0.194 mmol) 
and TFA (593 L, 7.8 mmol) to give 9 as a fluffy white solid (57 mg, 52%). 1H NMR (DMSO-
d6, 400 MHz)  9.54 (d, 1H, J = 8.2 Hz), 8.45 (bs, 2H), 7.22 (s, 2H), 6.73 (s, 1H), 5.65 (dd, 1H, 
J = 4.8 Hz, J = 7.9 Hz), 5.24 (d, 1H, J = 11.7 Hz), 5.06 (d, 1H, J = 4.9 Hz), 4.77 (d, 1H, J = 
11.8 Hz), 3.83 (s, 3H), 3.76 (t, 2H, J = 11.6 Hz), 3.47 (d, 1H, J = 17.4 Hz), 3.30 (d, 1H, J = 
17.5 Hz), 2.83 (t, 2H, J = 10.9 Hz), 2.72 (d, 2H, J = 6.0 Hz), 1.83 (d, 2H, J = 12.0 Hz), 1.75 
(m, 1H), 1.32 (t, 2H, J = 11.1 Hz). 13C NMR (DMSO-d6, 100 MHz)  168.4, 164.3, 163.0, 
162.4, 149.1, 142.6, 134.6 (observed in gHMBC), 113.4 (observed in gHMBC), 108.9, 73.0, 
61.9, 58.2, 57.5, 50.3, 50.2, 43.0, 32.8, 27.44, 27.38, 25.7. ESI-HRMS calcd. for 570.1548 




oxide (AMINOPIP2-cefepime 10) 
Compound 10 was prepared using General Procedure III from 38 (200 mg, 0.191 mmol) 
and TFA (585 L, 7.6 mmol) to give 10 as a fluffy white solid (51 mg, 46%). 1H NMR (DMSO-
d6, 400 MHz)  9.54 (d, 1H, J = 9.54 Hz), 8.27 (bs, 2H), 7.22 (s, 2H), 6.73 (s, 1H), 5.65 (dd, 
1H, J = 7.9 Hz, J = 4.8 Hz), 5.22 (d, 1H, J = 11.7 Hz), 5.05 (d, 1H, J = 4.8 Hz), 4.79 (d, 1H, J 
= 11.6 Hz), 3.83 (s, 3H), 3.77-3.70 (m, 2H), 3.46 (d, 1H, J = 17.5 Hz), 3.35-3.25 (m, 1H, 
overlapped by H2O, observed in gHSQC), 2.85-2.77 (m, 4H), 1.76 (d, 2H, J = 12.6 Hz), 1.52-
1.40 (m, 3H), 1.28-1.17 (m, 2H). 13C NMR (DMSO-d6, 100 MHz)  168.4, 164.1, 163.0, 162.3, 
149.1,142.6, 135.3 (observed in gHMBC), 113.1 (observed in gHMBC), 108.9, 73.0, 61.8, 
58.2, 57.5, 50.9, 50.8, 36.4, 32.9, 31.5, 30.0, 29.9. ESI-HRMS calcd. for 584.1704 [M+H]+ 




2-en-3-yl)methoxy)diazene 1-oxide (AMINOPIP1-ceftazidime 11) 
Compound 11 was prepared using General Procedure III from 39 (200 mg, 0.172 mmol) 
and TFA (659 L, 8.6 mmol) to give 11 as a fluffy white solid (43 mg, 39%). 1H NMR (DMSO-
d6, 500 MHz)  10.17 (bs, 1H), 8.38 (bs, 2H), 7.25 (bs, 2H), 6.73 (s, 1H), 5.77 (dd, 1H, J = 7.7 
Hz, J = 5.0 Hz), 5.11 (d, 1H, J = 5.0 Hz), 5.04 (d, 1H, J = 12.0 Hz), 4.97 (d, 1H, J = 12.0 Hz), 
3.82 (d, 2H, J = 11.2 Hz), 3.50 (d, 1H, J = 17.7 Hz), 3.37 (d, 1H, J = 17.9 Hz), 2.92 (d, 1H, J 
= 11.4 Hz), 2.87 (d, 1H, J = 11.4 Hz), 2.68 (d, 2H, J = 6.1 Hz), 1.82-1.68 (m, 3H), 1.46 (s, 3H), 
1.43 (s, 3H), 1.38-1.17 (m, 2H). 13C NMR (DMSO-d6, 125 MHz)  176.3 (observed in 
gHMBC), 168.4, 163 7, 163.3, 163.2, 149.7, 142.9, 132.0 (observed in gHMBC), 117.2 
(observed in gHMBC), 109.8, 82.3, 72.0, 58.4, 57.7, 49.9, 43.0, 32.8, 26.7, 25.5, 24.4, 23.9. 




en-3-yl)methoxy)diazene 1-oxide AMINOPIP2-ceftazidime 12) 
Compound 12 was prepared using General Procedure III from 40 (200 mg, 0.170 mmol) 
and TFA (652 L, 8.5 mmol) to give 12 as a fluffy white solid (37 mg, 33%). 1H NMR (DMSO-
d6, 500 MHz)  9.96 (bs, 1H), 8.27 (bs, 2H), 7.26 (bs, 2H), 6.74 (s, 1H), 5.75 (dd, 1H, J = 7.7 
Hz, J = 5.0 Hz), 5.13 (d, 1H, J = 11.9 Hz), 5.09 (d, 1H, J = 5.0 Hz), 4.85 (d, 1H, J = 11.9 Hz), 
3.79-3/73 (m, 2H), 3.49 (d, 1H, J = 17.5 Hz), 3.33 (d, 1H, J = 17.5 Hz), 2.83-2.76 (m, 4H), 
1.72 (d, 2H, J = 11.6 Hz), 1.46 (s, 3H), 1.43 (s, 3H), 1.49-1.40 (m, 2H, overlapped, observed 
in gHSQC), 1.49-1.40 (m, 1H, overlapped, observed in gHSQC), 1.25-1.16 (m, 2H). 13C NMR 
(DMSO-d6, 125 MHz)  176.0, 168.4, 164.0, 163.2, 163.1, 149.6, 142.8, 133.8 (observed in 
gHMBC), 115.1 (observed in gHMBC), 109.8, 82.2, 72.5, 58.4, 57.6, 50.8, 50.7, 36.4, 32.9, 
31.5, 29.7, 25.7, 24.4, 23.9. ESI-HRMS calcd. for 678.1735 [M+Na]+ C24H33N9O9S2Na, found 
678.1727. 
 
General Procedure IV (Compounds 32 and 33) 
N-Boc-4-alkylamino piperidines 30 and 31 (2.5 g) were dissolved in a mixture 
containing 10 mL of anhydrous 25% sodium methoxide/methanol and 40 mL of anhydrous 
diethyl ether in a Paar-Knorr reaction vessel. The mixture was purged with nitrogen (bubbling 
for 15 mins) before the reaction vessel was sealed and charged with nitric oxide gas at 50 psi. 
After shaking for 48 h the white precipitate was collected by vacuum filtration under argon, 
washed with copious dry diethyl ether (under argon) and dried under vacuum. 
 
N-Boc-AMINOPIP1/NO 32 
Compound 32 was prepared using General Procedure IV from 30 (2.50 g, 11.7 mmol) 
to give 32 as a white solid (3.11 g, 90 %). 1H NMR (DMSO-d6, 500 MHz)   6.86 (bs, 1H), 
2.94 (d, 2H, J = 10.7 Hz), 2.88-2.81 (m, 4H), 1.68 (d, 2H, J = 11.5 Hz), 1.37 (bs, 9H), 1.36-
1.39 (m, 1H, overlapped), 1.26 (qd, 2H, J =11.8 Hz, J = 3.5 Hz). 13C NMR (DMSO-d6, 125 
MHz)  155.8, 77.4, 51.9, 45.1, 35.3, 28.9, 28.3. 
 
N-Boc-AMINOPIP2/NO 33 
Compound 33 was prepared using General Procedure IV from 31 (2.50 g, 10.9 mmol) to give 
33 as a white solid (3.16 g, 93 %). 1H NMR (DMSO-d6, 500 Hz)   6.78 (t, 1H, J = 5.4 Hz), 
2.97-2.84 (m, 6H), 2.88-2.81 (m, 4H), 1.76-1.69 (m, 2H), 1.37 (bs, 9H), 1.34-1.24 (m, 5H).13C 
NMR (DMSO-d6, 125 MHz)  155.6, 77.3, 51.8, 37.5, 35.9, 32.0, 31.1, 28.3. 
 
P. aeruginosa strain history and growth conditions 
 
 P. aeruginosa laboratory strain PAO1 was obtained from the University of Washington, 
USA. Clinical isolates of P. aeruginosa were obtained from the University of Southampton’s 
culture collection, originally isolated from the sputum of CF patients based at University 
Hospital Southampton NHS Foundation Trust, UK. The mean age at informed consent was 28, 
with a range of ages from 19 to 65 years (NHS Research Ethics Committee 08/H0502/126). 
Details relating to the patients are provided in the Supporting Information Table S1. CF 
physiotherapists assisted patients with expectoration of sputum into sterile containers. The 
sputum was digested with Mucolyse (Pro-lab Diagnostic) containing dithiotheritol (DTT) and 
phosphate buffer for 15 min at 37 ˚C. P. aeruginosa was selected using cetrimide agar (Sigma 
Aldrich); a sterile loop was then drawn across the plate for a random selection of strains, which 
were frozen down to form the culture collection. Multiplex polymerase chain reaction (PCR) 
was conducted to confirm P. aeruginosa in the samples. 
 Samples from the culture collection were streaked onto selective cetrimide agar (Sigma 
Aldrich) to confirm isolation of P. aeruginosa and single colonies were selected to prepare 
fresh bacterial stocks in cryovials containing beads (Fisher Scientific), kept at -80 ˚C. 
Overnight cultures were prepared by inoculating a single bead of the frozen stock into 10 ml 
of Luria Bertani (LB) broth (Formedium) and incubated at 37 ˚C with shaking at 180 rpm.  
 
P. aeruginosa clinical strain susceptibility testing 
 The minimum inhibitory concentrations (MIC) of C3Ds and cephalosporin antibiotic 
controls against the P. aeruginosa clinical isolates were determined using the broth 
microdilution method in accordance with Clinical Laboratory Standards Institute guidelines.33 
Two-fold serial dilutions of test compounds were prepared in a 96 well plate. Compound 
dilutions were transferred to a new 96 well plate in triplicate, followed by addition of inoculated 
cation-adjusted Mueller Hinton broth (CAMHB) broth, prepared by diluting an overnight 
culture 1 in 500 to achieve approximately 1 x 105 to 106 cells. A CFU count was carried out to 
confirm the exact cell number of the inoculum. Blank samples were prepared using compound 
dilutions and uninoculated CAMHB broth. The 96 well plates were incubated overnight at 37 
˚C and the OD values read at 584 nm using the FLUOstar Omega Microplate Reader (BMG 
Labtech). The MIC was recorded as the lowest concentration that inhibited bacterial growth, 
as determined by visible turbidity. 
 
-lactamase activity of P. aeruginosa CF clinical isolates relative to PAO1 
 A nitrocefin assay was used to measure the relative -lactamase activity in CF clinical 
isolates of P. aeruginosa compared to PAO1. In this assay, the chromogenic cephalosporin 
nitrocefin undergoes a quantifiable yellow to red colour change when hydrolysed by -
lactamases.31 P. aeruginosa isolates were grown overnight in LB broth, subcultured into fresh 
broth and grown to mid exponential phase. Nitrocefin (Cambridge Bioscience) was prepared 
in DMSO/PBS and added to the cultures to a final concentration of 50 g/mL. Absorbance at 
490 nm was recorded at intervals during subsequent incubation, with an increase in OD490 
reporting -lactamase activity (Supporting information Figure S1). 
 
NO Release from C3Ds in the presence of commercial -lactamases 
 Nitric oxide (NO) was detected amperometrically using an Apollo 4000 free radical 
analyser (World Precision Instruments) fitted with an NO specific probe (ISO-NOP). A 
saturated solution of NO (1.91mM at 20 oC) was prepared by bubbling the gas into 10 mL of 
degassed distilled water for 10 min according to manufacturer’s instructions. A 10-fold dilution 
was performed giving a 191 M stock solution from which subsequent aliquots (10, 20, 40, 60, 
80 and 100 L) were diluted into 20 mL of PBS buffer (pH = 7.4, 2.7 mM KCl, 135 mM NaCl, 
1.75 mM KH2PO4, 10 mM Na2HPO4) to calibrate the instrument response. Baseline NO levels 
were monitored for 5 min in 20 mL PBS solution (pH = 7.4 at 25 oC) followed by injection of 
C3Ds 1, 4-12 (50 mM). NO levels were monitored for 15 min. Cleavage of the C3Ds was 
promoted by addition of 25 L 40 U.mL-1 P. aeruginosa -lactamase (Sigma, L6170) or 100 
L 40 U.mL-1 Bacillus cereus -lactamase (Sigma, 61305). After steady state NO 
concentrations were reached, a second aliquot of -lactamase was added. NO concentrations 
(nM) were established using a calibration curve. 
 
Cytotoxicity in HEK293 Cells 
 Growth inhibition of HEK293 cells was determined by measuring fluorescence at 
ex:530/10 nm and em:590/10 nm after the addition of resazurin (25 ug/mL final concentration) 
and incubation at 37 °C and 5% CO2 for additional 3 h. The fluorescence was measured using 
a Tecan M1000 Pro monochromator plate reader. The percentage of growth inhibition was 
calculated for each well, using the Negative Control (media only) and Positive Control (cell 
culture without inhibitors) on the same plate as references. CC50 (concentration at 50% 
cytotoxicity) were calculated by curve fitting the inhibition values vs. log(concentration) using 
a Sigmoidal dose-response function with variable values for bottom top and slope. 
 
Biofilm formation by P. aeruginosa CF clinical strains PA30 and PA68 
 P. aeruginosa clinical isolates PA30 and PA68 were confirmed to form reproducible 
ex-vivo biofilms using a crystal violet (CV) assay in 96 well microtitre plates. Biofilms were 
cultivated in M9 minimal media (pH 7; Formedium) containing 48 mM Na2HPO4, 22 mM 
KH2PO4, 9 mM NaCl, 19 mM NH4Cl, and supplemented with 2 mM MgSO4 (Sigma Aldrich), 
100 uM CaCl2 (Sigma Aldrich) and 20 mM glucose (Sigma Aldrich). Overnight cultures were 
diluted 1 in 100 into freshly prepared M9 minimal media and added into the wells of a flat-
bottom tissue culture-treated 96 well microtitre plate (Thermo Scientific) with a minimum of 
six replicate wells per strain. Well locations were altered such that, of the 6 replicate wells, 3 
were located near the edge of the plate and 3 near the centre of the plate to account for the 
effects of well location on biofilm growth. Uninoculated M9 minimal media served as the 
negative control. Four 96 well microtitre plates were set up for each strain for sacrificial 
analysis on days 1, 2, 3 and 5. Plates were incubated at 37 ˚C with daily media changes for 
biofilms grown for 2 or more days. Following the incubation period, the planktonic culture 
suspensions were gently aspirated and discarded. The wells were washed twice with PBS to 
remove any non-adherent cells. Biofilms were stained with 0.1% CV (Sigma Aldrich) for 15 
mins, and then rinsed with water 3 to 4 times, or until clear, and left to air dry overnight. CV 
stained biofilms were resolubilised in 30% acetic acid (Sigma Aldrich) for 20 mins and 
transferred to a new 96 well microtitre plate, and the absorbance measured at 584 nm 
(FLUOstar Omega Microplate Reader, BMG Labtech). Consistent and high absorbance 
readings were obtained with PA30 and PA68 on all days, confirming reproducible biofilm 
growth by both strains. 
 
Confirmation of NO-mediated biofilm dispersion by strains PA30 and PA68  
 The dispersal responses of biofilms grown from P. aeruginosa CF clinical strains PA30 
and PA68 to the spontaneous nitric oxide donor sodium nitroprusside (SNP) were examined 
using the CV microtitre plate assay. Briefly, overnight cultures were diluted 1 in 100 into 
freshly prepared M9 minimal media and added into flat-bottom tissue culture-treated 96 well 
microtitre plates (Thermo Scientific) and incubated at 37 ˚C for 24 h. Uninoculated M9 
minimal media served as the negative control. After incubation, the planktonic suspension was 
gently aspirated and discarded, and biofilms were washed once with M9 minimal media to 
remove non-adherent cells. SNP solution was prepared fresh in M9 minimal media, serially 
diluted, and added to wells containing biofilms. A minimum of 6 replicate wells were used for 
each treatment concentration, with the well locations randomized as previously described. 
Following incubation at 37 ˚C for a further 20 h, planktonic suspensions were transferred to a 
new 96 well plate and the absorbance measured at 584 nm. Biofilms were washed twice with 
PBS, stained with 0.1% CV for 15 mins, resolubilised in 30% acetic acid and the absorbance 
was measured at 584 nm. Absorbance readings confirmed dispersal responses of PA30 and 
PA68 ex-vivo biofilms to a range of SNP concentrations (Supporting Information Figure S2). 
 
Confocal laser scanning microscopy experiments with PA30 and PA68 biofilms 
 Overnight cultures of the strains were diluted 1 in 100 in M9 minimal media, and 2.5 
mL volumes were used to inoculate 35 mm glass-bottom microwell plates (MatTek 
Corporation). The plates were incubated at 37 ˚C with shaking at 50 rpm for 24 h to allow 
biofilm development. Biofilms were treated with test compounds solubilised in M9 minimal 
media and re-incubated at 37 ˚C for 3 h. Post-treatment, biofilms were washed twice with 
Hank’s balanced salt solution (HBSS) to remove non-adherent cells.  Biofilm viability was 
assessed using fluorescent dyes SYTO9 and propidium iodide (PI), as part of the LIVE/DEAD 
BacLight Bacterial Viability Kit (Life Technologies). SYTO9 stains bacterial cells with intact 
membranes green, whereas PI stains dead cells or cells with compromised membranes red.  
Following the manufacturer’s instructions,󠇖 stock solutions of each dye were diluted to 2 μg/mL,󠇖 
added to the glass-bottom microwell plates and incubated in the dark at room temperature for 
20 minutes. Biofilms were examined under an inverted Leica SP8 confocal laser scanning 
microscope using the x63 glycerol immersion lens and argon and DPSS laser lines at 488nm 
and 561 nm respectively,󠇖 with scanning at 1 μm intervals. A total of five replicate images were 
taken from each biofilm grown in the microwell plates. Imaged locations were kept constant 
and mathematically chosen to avoid bias; one image was taken at the centre of the well, and 
four images were taken at the centre of each theoretical well quadrant. Images were obtained 
and analysed using the LAS X software (Leica Microsystems GmbH). COMSTAT 2.0 software 
was used for quantitative analysis of images. The parameters calculated by COMSTAT 
included: (1) Total Biomass (μm3/μm2) = volume of biological material occupied by the biofilm 
divided by the substratum area, (2) Thickness Distribution (μm) = average thickness of the 
biofilm calculated from a list of the thicknesses of biofilm structures and their prevalence. This 
measure ignores the presence of pores or voids within the biofilm, (3) Maximum Height (μm) 
and (4) Total Surface Area coverage (μm2) are descriptors of the entire biofilm formed on the 
microwell plate substratum. 
 
Murine P. aeruginosa lung infection model 
Dose-escalation studies performed prior to the infection model 
(i) Animals: Male Institute of Cancer Research (ICR) mice weighing 25 ± 5 g were provided 
by BioLasco Taiwan (under Charles River Laboratories License). Animals were acclimated for 
3 days prior to use and were confirmed to be in good health. All animals were maintained in a 
hygienic environment with controlled temperature (20 – 24 ºC), humidity (30% - 70%) and 12 
hour light/dark cycles. Free access to sterilized standard lab diet [MFG (Oriental Yeast Co., 
Ltd., Japan)] and autoclaved tap water were made available. All aspects of this work, including 
housing, experimentation, treatments and disposal of animals, were performed in accordance 
with the Guide for the Care and Use of Laboratory Animals: Eighth Edition (National Academy 
Press, Washington, D. C., 2011) in an AAALAC-accredited animal laboratory facility. The 
animal care and use protocol was reviewed and approved by the Institutional Animals Care and 
Use Committee (IACUC) at Pharmacology Discovery Services Taiwan, Ltd. 
 
(ii) Protocol: AMINOPIP2-ceftazidime 12 was administered via subcutaneous injection (SC) 
to groups of three male ICR mice. The compound was formulated in water for injection (WFI) 
at 10, 15, 20 and 60 mg/mL and administered at 5 mL/kg. Animals received an initial dose of 
50 mg/kg. If the animals survived for 72 hours, the dose was increased for the next cohort to 
100 mg/kg. If the animals survived for 72 hours after 100 mg/kg, the dose was increased to the 
highest tested dose 300 mg/kg for the next cohort. Full clinical examinations and body weight 
changes were assessed. At each dose level, animals were observed for the presence of acute 
toxic symptoms (mortality, convulsions, tremors, muscle relaxation, sedation, etc.) and 
autonomic effects (diarrhoea, salivation, lacrimation, vasodilation, piloerection, etc.) during 
the first 30 minutes, and again at 1 hour (Supporting Information Table S6). Body weights are 
recorded pre-dose and at 72 hours (Supporting Information Table S7). The animals were 
observed and mortality noted daily (Supporting Information Table S8). 
 
Plasma and lung pharmacokinetics of AMINOPIP2-ceftazidime 12 in mice after subcutaneous 
dosing  
(i) Protocol: AMINOPIP2-ceftazidime 12 was dissolved in water for injection and 
administered via SC injection at 75 mg/kg (5 mL/kg) to male ICR mice weighing 20-30 g (n = 
3). Drug-free mice (n = 3) were included as controls. Blood aliquots (300-400 μL) were 
collected via cardiac puncture from individual anesthetized mice 5, 15, 30, 45, 60, 180, 360 
mins after injection in tubes coated with lithium heparin, mixed gently, then kept on ice and 
centrifuged at 2,500 ×g for 15 minutes at 4°C, (within 1 hour of collection). For control 
animals, blood was collected by cardiac puncture. The plasma was then harvested and kept 
frozen at -70 °C until further processing. Immediately after blood sampling, the whole lungs 
were quickly removed, rinsed with cold saline (0.9 % NaCl, g/mL), blotted with dry gauze, 
weighed, and kept at -70 °C until further processing. Lungs were homogenized in an 
appropriate volume of cold PBS (pH 7.4) for 10 seconds on ice. The lung homogenate was then 
stored at -70 °C until further processing. 
 The plasma samples were processed using acetonitrile precipitation and analyzed by 
LC-MS/MS. A plasma calibration curve was generated from aliquots of drug-free plasma 
spiked with AMINOPIP2-ceftazidime 12 at the specified concentration levels (Supporting 
Information Figure S3(a)). The spiked plasma samples were processed together with the 
unknown plasma samples using the same procedure. The processed plasma samples were 
stored at -70 °C until LC-MS/MS analysis, at which time peak areas were recorded and the 
concentrations of AMINOPIP2-ceftazidime 12 in the unknown plasma samples determined 
using the calibration curve. 
 Each lung homogenate was centrifuged at 5400 ×g for 15 minutes at 4 °C. Supernatants 
were subsequently processed using acetonitrile precipitation and analyzed by LC-MS/MS. A 
lung calibration curve was generated from aliquots of drug-free lung homogenate spiked with 
AMINOPIP2-ceftazidime 12 the specified concentration levels (Supporting Information Figure 
S3(b)). The spiked lung homogenate samples were processed together with the unknown lung 
homogenate samples using the same procedure. The processed lung samples were stored at -
70°C until the LC-MS/MS analysis, at which time peak areas were recorded and the 
concentrations of AMINOPIP2-ceftazidime 12 in the unknown lung samples were determined 
using the appropriate calibration curve. Plots of plasma and lung concentration of 
AMINOPIP2-ceftazidime 12 versus time were constructed (Figure S4(a) and S4(b), 
respectively) and lung:plasma ratios calculated (Supporting Information Table S9). 
 
Infection model protocol 
 Pseudomonas aeruginosa strain FDA-CDC AR-BANK#0264 was received from the 
FDA-CDC AR Bank in 2017 and cryopreserved as single-use frozen working stock cultures, 
stored at -80 oC. The stock was thawed at room temperature prior to use. A 0.2 mL aliquot was 
inoculated into 20 mL Tryptic soy broth (TSB) and incubated at 35-37 oC with shaking (250 
rpm) for 6 h. One mL of the 6 h culture was used to seed 99 mL TSB and incubated at 35-37 
oC with shaking at 250 rpm for 16 h. Cells in 20 mL culture were pelleted by centrifugation 
(3,500 × g) for 15 minutes and re-suspended in 10 mL cold PBS >1 × 109 CFU/mL, OD620 1.2-
1.6. The culture was diluted in PBS to a target inoculum of 5 × 107 CFU/mL. The actual colony 
counts were determined by plating dilutions onto nutrient agar (NA) plates followed by 
incubation for 20-24 h. The CFU counts were 4.55 × 106 CFU/mL.  
 Groups of 5 female Bltw:CD1 (ICR) mice weighing 22 ± 2 g were used. Animals were 
immunosuppressed by two intraperitoneal injections of cyclophosphamide, the first 150 mg/kg 
4 days before infection (Day –4) and the second 100 mg/kg 1 day before infection (Day –1). 
On day 0, animals were anesthetized with etomidate-lipuro emulsion (20 mg/10 mL; 20 mg/kg 
IV) and inoculated intranasally with P. aeruginosa FDA-CDC AR-BANK#0264 suspension 
(0.02 mL/mouse). The target inoculation density was 1.0 × 106 CFU/mouse and the actual count 
was 9.1 × 105 CFU/mouse. Vehicle (5% DMSO in 0.9% NaCl), AMINOPIP2-ceftazidime 12 
and ceftazidime (both at two doses; 50 and 120 mg/kg in 5% DMSO in 0.9% NaCl) were 
administered subcutaneously (SC) six times at 4 hr intervals (q4h) starting 2 hr after infection 
for a total dose of 300 and 720 mg/kg over 24 h. Animals were sacrificed 26 h after inoculation 
by CO2 asphyxiation and the lung tissues were harvested and weighed for each of the test 
animals. The removed lung tissue was homogenized in 1 mL sterile PBS (pH 7.4) and stored 
on ice for up to 2 h. Serial 10-fold dilutions in PBS were generated. Aliquots of the dilutions 
(100 μL) were separately plated onto MacConkey II agar plates for bacterial enumeration. The 
bacterial counts (CFU/g) in lung tissue homogenates were calculated and the percentage 
decrease in counts compared to the corresponding vehicle control was calculated using the 
formula: 
 
Decrease (%) = [(CFU/g of vehicle –CFU/g of treatment)/ (CFU/g of vehicle)] x 100% 
 
 One-way ANOVA with Tukey’s multiple comparisons test was performed to assess statistical 
difference in the lung bacterial counts for the AMINOPIP2-ceftazidime 12 and ceftazidime-
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